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Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Withington, Manchester M20
6BX, UK.
The haemopoietic system is normally maintained in
dynamic equilibrium and when this equilibrium is
disturbed the system responds quickly to re-
establish it. This presentation will focus upon the
behaviour of the haemopoietic progenitor and
precursor cells responsible. I shall take
erythropoiesis as the example of a cell system
committed to the production of a specific end
product and consider the pluripotent stem cells
from which all haemopoietic cells derive. In the
haemoglobinising (and therefore recognisable)
erythroid cells there is flexibility in the degree of
amplification they can undergo during periods of
high demand. In the erythroid precursor cells which
cannot be recognised morphologically (but which
can be recognised functionally) there is considerable
overproduction which is exploited immediately
when there is increased demand. There is also an
increased production of these precursor cells. The
normal production and enormous reserve
production capacity is maintained throughout life
and would, if necessary, function for several
lifespans. The supply originates within the
haemopoietic tissues and depends upon a stem cell
population committed solely to the production of
blood cells. The stem cells are essentially
"immortal" insofar as the animal's life-span is
concerned. Overwhelming evidence now implicates
a highly specific cellular microenvironment as being
responsible for the survival and self-renewal of
these cells. Microenvironmental influences also
determine their rate of production and direction of
differentiation.
Proliferation control mechanisms in haemopoiesis
E.G. Wright
Department ofAnatomy andExperimental
Pathology, The University ofSt Andrews, Fife KY16
9TS, UK.
Mammalian haemopoietic tissue can be represented
as a three-tier hierarchy of cell compartments: stem
cells, committed precursor cells and maturing cells.
Stem cells in murine tissues are detected by their
ability to produce macroscopic colonies of
haemopoietic cells in the spleens of irradiated mice
and are therefore operationally defined as colony
forming units - spleen (CFU-S). An essential
feature of stem cells is their capacity for "self-
renewal". It is generally accepted that loss of self-
renewal potential occurs concomitantly with an
irreversible commitment to a more restricted
potential for differentiation. Committed precursor
cells (also known as progenitor cells) are detected
by functional in vitro assays. They are
operationally defined as colony-forming cells (CFC)
that produce clones of morphologically-identifiable,
maturing haemopoietic cells when appropriately
stimulated.
Regulatory factors controlling the proliferative
behaviour of cells at various stages in their
developmental history have been demonstrated and
it is becoming clear that- control of cellular
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proliferation in haemopoietic tissues is effected by a
series of integrated inhibitor/stimulator negative
feedback loops. There is increasing evidence that
the distribution of proliferating and differentiating
cells within the bone marrow is not random and
that the various cell compartments conform to well
defined spatial distributions in the marrow spaces.
It is likely that the bone marrow has a spatial
organisation related to the regulation of
haemopoietic cell production.
The role of stromal cells and growth factors in
normal haemopoiesis and leukaemogenesis
T.M. Dexter, A.D. Whetton & G. Bazill
Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Withington, Manchester
M20 9BX, UK.
Haemopoiesis in the adult occurs mainly in the
bone marrow, where the developing blood cells are
found in intimate association with a variety of
stromal cell types. Evidence indicates that the
stroma is not simply supplying a "lodgement" area
for the haemopoietic cells, but is actually having a
determinative role to play in haemopoietic cell
development by producing a variety of regulatory
molecules essential for the survival, proliferation
and differentiation of the primitive blood cells.
Developing leukaemic cells, like normal cells,
demonstrate an absolute dependence on the stromal
cells/regulatory factors and rapidly die in their
absence.
Recently, we have purified a haemopoietic cell
growth factor (HCGF) which may represent a
"master-control" molecule in haemopoiesis in that
the growth factor a) facilitates self-renewal and
differentiation of pluripotent stem cells, b)
stimulates the committed myeloid progenitor cells
and c) "immortalises" granulocyte precursor cells
and allows their growth in the absence of stroma.
HCGF. acts by modulating energy levels in the
haemopoietic cells via its effect on glucose
transport. The evolutionary significance of this
finding and its relation with leukaemogenesis will
be discussed.
Molecular analysis of erythropoiesis
P.R. Harrison, N. Affara, P.S. Goldfarb, K.
Kasturi, E. Black, J. Fleming & J. O'Prey
The Beatson Institutefor Cancer Research, Glasgow,
UK.
Erythropoiesis involves the sequential expression of
a series of characteristic red cell proteins during
differentiation of committed erythroid progenitor
cells, proteins such as spectrin and glycophorin,
followed by the globins haem and other
characteristic enzymes such as carbonic anhydrase,
catalase and a specific lipoxygenase. It had been
generally believed that spectrin and glycophorin,
like the globins, were specific to red cells. But
recent evidence by our group and others has shown
that spectrin and possibly glycophorinlike molecules
exist in certain other cells (Kasturi et al. (1983)
Exp. Cell Res., 144, 241). This implies that red cell
differentiation involves the tissue-specific regulation
of gene families coding for spectrin and possibly
glycophorin and other red cell proteins.
A major aspect of our recent work has involved
cloning genes or mRNAs coding for characteristic
red cell proteins (Affara et al. (1983) Nucl. Acids
Res., 11, 931; Goldfarb et al. (1983) Nucl. Acids
Res., 11, 3517.) with a view to elucidating the
chromosomal and transcriptional changes involved
in the expression of these genes during red cell
differentiation. In particular, we have studied the
molecular/genetic mechanisms of co-ordinate
control of globin and non-globin genes by
measuring their nuclease sensitivity, DNA
methylation and transcription patterns in cell
hybrids between erythroblasts and other cell types.
Symposium on "Cellular Oncogenes"
Organizedjointly with the British Societyfor Cell
Biology.
Specific genes involved in oncogenesis
R.A. Weiss
Institute of Cancer Research, Fulham Road, London
SW3 6JB, UK.
Carcinogenesis has long been recognised as a
stepwise process, probably involving genetic change
at several stages. The advance in our understanding
of the genetics of cancer in recent years has been
the identification of specific genes that play a role
in malignant transformation, The transforming
genes of tumour viruses have been studied most
thoroughly. While the oncogenic properties of
DNA tumour viruses appear to result from the
expression of genes essential for viral replication,
the oncogenes of retroviruses are derived from
cellular genes and play no role in the life-cycle of
the virus. The cellular homologues of several
oncogenes have been found in changed form in
human tumours. Human oncogenes have beenPROCEEDINGS OF BACR 25TH AGM 241
detected by (a) tumour DNA transferred to cell
lines sensitive to oncogene transformation, (b)
amplified sequences in the tumour cells, and (c)
chromosome translocations associated with specific
types of malignancy. Some of the oncogenes
detected by DNA transfer have not previously been
found in viral genomes. Some oncogenes are
regularly activated in experimental systems of
chemical carcinogenesis; others - oncofetal genes -
are normally expressed during embryogenesis and
become reactivated during viral or chemical
transformation. The regulation of these genes and
the properties of their products will be briefly
reviewed as an introduction to the subsequent talks.
Activated ras oncogenes in human & mouse tumours
C.J. Marshall, A. Hall, R.J. Brown, Karen
H. Vousden & Hugh Paterson
Institute ofCancer Research, Fulham Road, London
SW3 6JB, UK.
We have identified the activated transforming gene
in HT 1080 fibrosarcoma cells as a new member of
the ras gene family. In HT1080 cells the N-ras gene
is activated by an amino acid substitution of
glutamine by lysine. This substitution results from a
transversion, such that the mRNA contains an AAA
codon instead of CAA.
In order to investigate the biological role of ras
genes we have introduced the cloned genes into a
variety of cell types. The transforming gene of
HTIO8O cells has been introduced into flat
revertants of HT1080. Such transfected revertants
become transformed, demonstrating that HT1080
can respond to its own activated N-ras gene. This
result implies that the N-ras gene plays a role in the
transformed phenotype of HT1080 tumour cells.
Analysis of the avian erythroblastosis virus erb B
oncogene products
M.J. Hayman', G. Kitchenerl'2 & H. Beug2
'Imperial Cancer Research Fund, London WC2,
U.K. and 2European Molecular Biology Lab.,
Heidelberg, FRG.
The avian erythroblastosis virus AEV, causes two
diseases in young chickens, erythroblastosis and
fibrosarcoma. The oncogene responsible for these
diseases is known as erb, and it is capable of
producing two gene products, erb B which is
primarily responsible for both diseases, and erb A
which plays an, as yet undefined, ancilliary role in
transformation. Data will be presented on the
biosynthesis of the erb B glycoprotein in both wild-
type virus transformed cells and cells transformed
by temperature-sensitive mutant virus. The results
of these experiments show that surface expression
of erb B correlates with transformation, and
suggests that erb B may be functioning as a growth
factor receptor-like molecule to induce the
uncontrolled proliferation of the fibroblasts and
erythroid cells it transforms.
Papillomaviruses
W.F.H. Jarrett
Department of Veterinary Pathology, University of
Glasgow Veterinary School, Bearsden, Glasgow
G61 JQH, UK.
Papillomaviruses are not known to interact with
any cellular oncogene. Bovine papillomaviruses I
and 2 transform primary fibroblasts in tissue
culture and also rodent cells. Using this system in
transfection assays it has been shown that a
fragment comprising 69% of the viral genome is
required for transformation. This fragment contains
two genes which give rise to five transcripts.
Current work on the structure and action will be
presented.
Activation of cellular genes in transformed cells
P.W.J. Rigby, P.M. Brickell, D.S. Latchman,
D. Murphy, M.R.D. Scott, K-H. Westphal &
K. Willison
Cancer Research Campaign Group
Department ofBiochemistry, Imperial College and
Chester Beatty Laboratories, Institute ofCancer
Research, London, UK.
We have used molecular hybridisation and cDNA
cloning techniques to isolate a number of cellular
genes which are transcriptionally activated in a
variety of murine transformed and tumour cell
lines. These cDNA clones have been used both to
characterise the corresponding genomic sequences
and to analyse gene expression in tumour cells. The
cDNA clones of Set 1 define a Major
Histocompatibility Complex gene from the Qa/Tla
region, the activation of which is a general feature
of oncogenesis in the mouse. The inappropriate
expression of this embryonic MHC antigen has a242 PROCEEDINGS OF BACR 25TH AGM
number of interesting immunological implications.
cDNA clones of Set 2 define an endogenous C-type
retrovirus which is activated in a number of
transformed cell types. cDNA clones from several
other Sets derive from inappropriate processing of
transcripts from the mitochondrial genome. This
experimental approach has allowed us to define a
number of ways in which the cell responds to the
expression of an oncogene.
Oncogenes of adenoviruses
P.H. Gallimore
Department ofCancer Studies, University of
Birmingham, Medical School, Birmingham, B15 2TJ,
U.K.
Human adenoviruses can be divided into oncogenic
and non-oncogenic serotypes. Most adenoviruses
transform rodent cells and the gene regions
participating in transformation have been
determined. Recent studies have focused on Early
Region 1 (El) which contains two transcription
units Ela and Elb. The development of Ela and
Elb mutants and intratypic recombinant plasmids
with DNA transfection studies indicate that the
interaction of adenovirus genes in transformation
and tumour induction is complex. Expression of
Ela alone only produces rare "atypical
transformants". Mutations in Ela or Elb can
abolish the transforming and tumourigenic
phenotype. Our knowledge of El proteins will be
discussed in the light of our current understanding
of the properties of other oncogenes.
Oncogenes may encode a growth factor or part of the
receptor for a growth factor
M.D. Waterfield
Protein Chemistry Laboratory, Imperial Cancer
Research Fund, Lincoln's Inn Fields, London WC2A
3PX, U.K.
Studies of the structure of platelet derived growth
factor (PDGF) have shown that simian sarcoma
virus has acquired cellular sequences which encode
a protein almost identical to the precursor of one
polypeptide chain of PDGF (Waterfield et al.,
Nature 304, 35, 1983; Johnsson et al., to be
published). This polypeptide is a growth factor
(Deuel et al., 1983, Science, 221, 1348) and related
mRNA transcripts and polypeptides have been
detected in human tumour cell lines which would be
expected to respond to a PDGF-like molecule (glial
and connective tissue - Eva et al., 1982, Nature,
295, 116; Heldin et al., 1980, J. Cell. Physiol., 105,
235). This suggests that "Autocrine" growth factor
production would play a role in abnormal growth
control of transformed or tumour derived cell lines.
Recent studies of the amino acid sequence of
immunoaffinity purified EGF receptors have shown
that the v-erb-B oncogene may encode a truncated
receptor lacking the external ligand binding domain
(Downward et al., 1984, Nature, in press). This
result suggests that an alternative to autocrine
growth factor expression is subversion of a receptor
function. Since the v-erb-B oncogene is related to
the src subset of retroviral oncogenes other putative
transforming proteins may be related to other
growth factor receptors. The implications of these
two observations will be discussed.
Abstracts of members' proferred papers
Phase I clinical trial of CB3717 (N-(4-(N-(2-amino-
4-hydroxy-6uinazolinyl)methyl)prop-2-
ynylamino)benzoyl-L-glutamic acid)
D.L. Alison, B. Robinson, S.J. Harland, B.D.
Evans & A.H. Calvert
Royal Marsden Hospital, Sutton and London, UK.
The quinazoline folate analogue CB3717 is a potent
thymidylate synthetase inhibitor. A phase I clinical
trial was carried out at the Royal Marsden
Hospital recruiting 101 patients. The schedule of
administration was a one hour infusion of the drug
dissolved in 250ml of 0.15NaHCO3 at pH9.0
repeated every 3 weeks. Doses were escalated from
140 mgm 2 to 600mgm-2 which was the
maximum tolerated dose. The dose limiting toxicity
was renal, and predicted by preclinical studies with
significant reduction in 5tCr EDTA clearances
(>50%) occurring with increasing frequency at
doses of 500-600mgm-2. Below 500mgm-2
reduction of 20-50% pretreatment GFR occurred
occasionally. Reversible hepatic toxicity typified by
a rise in alanine transaminase levels occurred
frequently (80% patients with increase to 1-2 times
normal, 50% patients with increase >2 times
normal) and was associated with malaise of several
days duration. Alkaline phosphatase levels also rose
but to a lesser extent. Prolongation of the infusion
time to 12h did not affect either the incidence or
severity of this toxicity which was seen at all dose
levels. Administration of prednisolone 30mg dailyPROCEEDINGS OF BACR 25TH AGM 243
for 1/52 after treatment ameliorated the malaise but
not the biochemical lesion. In 17 patients the WBC
was suppressed (nadir day 10, recovery days 14-16)
and in 6 thrombocytopenia developed. Ten patients
developed rashes. Neither the myelotoxicity nor the
skin toxicity was dose related. The following
responses were observed in evaluable patients at
doses between 200-600mgm-2: ovary 1CR, I PR,
7 MR/30; breast 3PR, I MR/8; lung - adenoca
1 PR, 1 MR/8; bowel 2MR/5; mesothelioma 1 PR/5.
We conclude that CB3717 deserves Phase II
evaluation for which we recommend the relatively
non-toxic dose of 400mgm2.
Results of a clinical phase I study of 1,2,4,
triglycidylurazole (TGU NSC 332488) with
pharmacokinetic profile
M. Soukop, F. Stuart, D. Cunningham, N.
Gilchrist, G. Forrest & A. Setonoian
Department ofMedical Oncology, Glasgow Royal
Infirmary and Department ofClinical Oncology,
Glasgow University, Scotland, UK.
Thirty one patients with advanced malignancies
received TGU in a phase I study. Therapy was
given initially by push injection in physiological
saline at 3 weekly intervals. Dose escalation from
30mgm-2 to 900mgm-2 was used with a
minimum of 3 patients at each dose level.
Myelosuppression was dose-limiting and when it
occurred resulted in a white count nadir at
16.5+7.5 days with recovery at 34.5+17.6 days.
Platelet nadir 15.4+6.3 days (recovery 36.8+21.7
days). Side effects in patients treated with 800 or
900mgm-2 were as follows: nausea and vomiting
(WHO grade) 0 in 1 course, 2 in 9 and 3 in 12
courses. Alopecia minimal in 1 patient. When TGU
was given by infusion for pharmacokinetic reasons
2 cases of severe thrombophlebitis were observed.
This severity of local toxicity was not seen with
bolus administration. No renal, hepatic or cardiac
toxicity were seen. Two minor clinical responses
and one partial response (PR) were seen. The PR
occurred in a patient with an unknown primary
(adenocarcinoma) resistant to prior therapy with
5FU, Adriamycin and Mitomycin-C.
An HPLC analytical method has been developed
with a sensitivity of 10l igml-l' The data obtained
fit a 2 compartment pharmacokinetic model with a
biexponential decay of very short T-ci of 3.8min
and T-/# of 8.6min. In conclusion TGU appears to
be a new triepoxide worthy of Phase II study using
a dose of 800mgm-2 given q 3 or 4 weeks and
with acceptable, predictable toxicity.
Phase I clinical pharmacokinetics of CCRG 81010
(M & B 39565, NSC 353451)
C. Goddard, J.A. Slack, 1E.S. Newlands, 2G.
Blackledge, 1C.J. Brindley & M.F.G. Stevens
Cancer Research Campaign, Experimental
Chemotherapy Group, Department ofPharmacy,
University ofAston in Birmingham, 1Charing Cross
Hospital, London. 2Queen Elizabeth Hospital,
Birmingham
CCRG 81010 (8-Carbamoyl-3-(2-chloroethyl)-
imidazo (5,1-d)-1,2,3,5-tetrazin-4(3H)-one) is a novel
agent active against a wide range of murine
tumours and is currently undergoing Phase I
clinical evaluation. The drug was formulated as a
50mgml-1 solution in dimethyl sulphoxide and
diluted with 500ml of isotonic saline prior to
administration as a 1 h i.v. infusion. The trial began
in June 1983 at a dose of 8.0mgm2. Plasma
samples were collected over 24h and analysed for
parent drug by HPLC (Slack et al., 1983, PAACR,
24, 1152). The pharmacokinetic data currently
available is summarised below, with the data
expressed as means for each dose level:
Dose (mgm-2) 8.0 16.5 33.0 54.4
Number ofdoses 6 9 5 4
t-(h) 1.2 1.1 1.3 1.0
AUC (mghl-1) 0.855 1.410 2.510 4.729
Volume of
Distribution (1) 29.0 34.7 47.2 31.3
Dose (mgm-2) 82.0 115.0 153.0
Number of doses 4 5 3
t (h) 1.2 1.2 1.0
AUC (mghI-') 6.297 9.045 12.311
Volume of
Distribution (1) 40.4 43.7 38.5
The data appears to be in agreement with a single
compartment open model and the drugs elimination
from plasma (with t2 just in excess of 1 h) correlates
well with mouse studies. The maximum tolerated
dose is expected to be attained within 2 further
dose escalations. The bioavailability of oral
capsules and the excretion of 14C-labelled CCRG
81010 is currently under investigation.244 PROCEEDINGS OF BACR 25TH AGM
Human 2 interferon (IFN) (Schering Plough 30500)
in the non-Hodgkin lymphomas (NHL): A report of 2
phase II studies
J. Wagstaff & D. Crowther
CRC Department ofMedical Oncology, Christie
Hospital, Manchester, UK.
Eighteen patients with centrally reviewed
histologically confirmed CS III and IV low grade
NHL (DWDL=8, NPDL=5, NM =3) were treated
with 2 x 106IUm-2 IFN by sc injection 3 times per
week for 3 months. Five were previously untreated.
Patients with PR or static disease were continued
until progression or 1 year. The IFN was well
tolerated with mild subjective toxicity (myalgia,
malaise and tiredness), myelosuppression was mild
and there was no hepative toxicity. Six patients are
still on treatment. The median duration of
treatment was 3 months (0.25-12). One patient
achieved CR after 4 months therapy. She stopped
IFN after I year and remains disease free 2 months
later. Three others have achieved PRs (6 weeks, 3
months and 10 months+). Four are static (1
stopped, 3 continuing). This IFN has activity in
approximately 25% of these patients.
Seven patients with refractory high grade
NHL(DPDL =6, lymphoblastic= 1) were treated
with 250 x l06IU m-2 IFN as a 24h infusion at 3-4
weekly intervals. Median number cycles=3 (2-5).
Acute toxicity was severe (malaise, high fever,
rigors, nausea and vomiting). More chronic toxicity
(malaise, anorexia and lethargy) took 4-7 days to
resolve. Myelosuppression and hepatotoxicity were
rapid, mild and reversible. Four patients had rapid
disease regression which began to recur before the
next cycle. Only 2 of these qualified for PR. This
suggests that very high dose IFN is active in this
disease but that the more continuous scheduling
which would be required to prevent mid-cycle
progression may be intolerable.
Platinum (CP)-induced emesis. Evaluation of
dexamethasone (D) in combination with high dose
metoclopramide (HDM)
S.G. Allan, M.A. Cornbleet, M.W. Ramsay, P.S.
Warrington, R.C.F. Leonard & J.F. Smyth
Department ofClinical Oncology, Western General
Hospital, Edinburgh, UK.
In a randomised, double-blind study of 34 patients
undergoing treatment with CP for a variety of
malignancies, 102 treatment courses were given
using D+HDM or placebo (P)+HDM in random
sequences as the anti-emetic. The age range was 30-
67, mean 56 years. CP at 30mgm-2 was given on
60 courses and lOOmgm-2 on 42 courses. HDM
(5mgkg-1) made up in 500ml of normal saline was
infused in 100ml aliquots 1/2h before CP (1 h
infusion), and then 2 hourly thereafter. D(20mg)
or P (normal saline) was given by i.v. bolus prior to
the first HDM dose. 16-18 h after CP, a
questionnaire was completed to record the number
of dry retches (DR), vomits (V), meals eaten, bouts
of diarrhoea and side-effects related to anti-emetic
therapy. Nausea (N) was evaluated using a visual
analogue scale. Duration of nausea and vomiting
was recorded. The results are recorded as % of
courses under the following coding: A= free of all
N, DR+V; B=free of N; C=free of DR; D=free
of V; E= <l day duration N; F= <l day
duration V; G= diarrhoea; H=drowsiness.
A B C D E F G H
D+HDM 23 33 50 35 34 50 6 46
P+HDM 10 24 34 26 13 33 18 36
50% of patients in both groups ate all meals
offered during chemotherapy and an equal number
(35%) in both groups experienced tremulousness.
We conclude that D enhances the anti-emetic
efficacy of HDM and promotes more rapid
recovery from N+V induced by CP. D appears to
diminish the CP-induced diarrhoea and is not
associated with additional side-effects.
Lymphocyte migration in patients with non-
Hodgkin's lymphoma (NHL) and Hodgkin's disease
(HD): A novel form of therapy
J. Wagstaff, M. Birch, H. Sharma, W. Ford & D.
Crowther
Department ofMedical Oncology, Christie Hospital,
Departments ofCellular Immunology and Medical
Physics, University ofManchester, UK.
The lymphocyte is a nomadic cell and those seen
within the blood are destined soon to leave it, to
traverse the tissues and thence to return to the
blood via the thoracic duct. Malignant lymphocytes
possess unique patterns of migration. For example
in patients with gastro-intestinal tract NHL the
disease frequently remains localised to the abdomen
despite there being lymphoma cells in the blood.PROCEEDINGS OF BACR 25TH AGM 245
We have studied the patterns of migration of
autologous lymphocytes labelled with indium-Ill
oxine in normal subjects (Wagstaff et al. (1981).
Clin. Exp. Immunol., 43, 435; Wagstaff et al., 1981,
Clin. Exp. Immunol., 43, 443). We present here the
results of studies in patients with HD and NHL.
Normal lymphocytes accumulate preferentially at
sites of disease in both NHL and HD. In HD this
phenomenon is sufficiently large to account for the
peripheral blood lymphopenia and impaired
reaction to cutaneously administered recall antigens
frequently seen in this disease. More recently
experiments in rats using lymphocytes labelled with
the fl-emitter 114In show that therapeutic doses of
radiation may be delivered to the lymphoid tissues
without undue toxicity. Similar experiments are
being conducted in man and preliminary data will
be presented. This approach promises to be a novel
therapeutic manoeuvre for selectively irradiating
sites of disease in both NHL and HD.
Heterogeneity of human natural killer (NK) cells at
the clonal level
K. Roberts & M. Moore
Department ofImmunology, Paterson Laboratories,
Christie Hospital & Holt Radium Institute,
Manchester M20 9BX, UK.
In human peripheral blood, most natural killer
(NK) cells are found in the null cell fraction,
morphologically identifiable as large granular
lymphocytes (LGL). However, analysis of purified
LGL with monoclonal antibodies to defined cell
surface determinants has shown them to comprise a
heterogeneous population. To determine whether
NK recognition structures are clonally distributed
we have recently developed human NK clones by
limiting dilution (LD) and expansion in interleukin-
2. While all of these have retained their
characteristic morphology, there is significant inter-
and intra-donor variation in the proportion of
cytotoxic clones developed and the specificity of
their reactions e.g. 14/32 clones from one LD were
cytotoxic of which 4 killed both K562 and Molt 4
targets, while 10 killed K562 only; another LD
yielded 3/9 cytotoxic clones of which 2 killed K562
but not Molt 4 and 1 killed both tragets. The
heterogeneity has been confirmed by comparative
cytotoxicity tests on a wider range of targets and
cumulatively the data indicate that target cell
recognition structures are clonally distributed. Some
dissociation between NK and K cell activities (the
latter assayed against antibody - sensitised
ARh(D)+ve erythrocytes) - normally attributed to
be different functions of the same cell type - has
also been observed.
Influence of phorbol acetate (TPA) on the
susceptibility of K562 to natural cytotoxicity:
Evidence for clonal variation in differentiation-
induced changes oflytic sensitivity
I. Kimberl & M. Moore
'Immunology Section, ICI, Central Toxicology
Laboratory, Alderley Park, Macclesfield, Cheshire
SKJO 4TJ; Department ofImmunology, Paterson
Laboratories, Christie Hospital & Holt Radium
Institute, Manchester M20 9BX, UK.
The effect of 12-0-tetradecanoylphorbol-13-acetate
(TPA) on the sensitivity to NK cell-mediated lysis
of 2 cloned populations of K562 which exhibit
marked and stable differences in their susceptibility
to natural cytotoxicity has been examined. Culture
in medium supplemented with concentrations of
TPA of 1 ngml - or greater invariably caused a
decrease in the susceptibility of the sensitive clone
ElO/P2 whereas treatment of the relatively resistant
clone F9/P2 with TPA under identical conditions
caused a significant increase in susceptibility to
natural cytotoxicity. In both cases the change in
susceptibility occurred within 1 day of culture in
TPA and was rapidly reversible following removal
of the inducing agent. The changes in resistance to
natural cytotoxicity induced by TPA were
independent of variations in osmotic fragility and
were not attributable to alterations in NK cell
binding capacity as determined by cold competition
analysis. In contrast to the effect of TPA, exposure
of E1O/P2 and F9/P2 to interferon (IFN) caused a
reduction in sensitivity to natural cytotoxicity of
both populations which was associated with a
decreased capacity to compete for lysis of labelled
target cells. These data suggest that the effects of
differentiating agents on target susceptibility to NK
cell lysis are variable and clonally distributed within
cell populations.
Inhibition of human natural killer (NK) activity by
alkylating ketones: Evidence for the involvement of
cell surface proteases in the lytic event
M.M. Dawson, U. Shipton & M. Moore
Department ofImmunology, Paterson Laboratories,
Christie Hospital & Holt Radium Institute,
Manchester M20 9BX, UK.
The lysis of target cells by Natural Killer (NK) cells
is a complex process that is probably mediated by
proteins in the effector cell plasma membrane.
Proteases have been implicated in the NK-mediated246 PROCEEDINGS OF BACR 25TH AGM
lysis of susceptible target cells since a variety of
molecules with anti-protease activity also inhibit
NK cytotoxicity in vitro (Hudig, et al., 1981, J.
Immunol., 126, 1569). K562 lysis by human NK
cells was used to study the effects of the small
molecular weight antiproteases tosyl-L-lysyl
chloromethyl ketone (TLCK) and tosyl-L-
phenylalanyl chloromethyl ketone (TPCK) which
are know to inhibit serine proteases by alkylation
of a histidine residue at the active site of the
enzyme (Shaw, et al., 1965, Biochemistry, 4, 2219).
Our studies indicate that the effects of TPCK and
TLCK are immediate and are manifested at the
effector level: Pretreatment of effectors for 30min
with either inhibitor was sufficient to inhibit lysis of
K562 whereas pretreatment of target cells was
ineffective. The effects of TLCK and TPCK were
irreversible and non-toxic: Lymphocytes pretreated
in this manner did not recover NK activity after 2
days in culture although they were still viable by
dye exclusion. Kinetic data derived from
experiments in which TLCK was added at different
time intervals after effector: target cell interaction
suggest that post-binding events are also affected by
this agent. The contribution of intracellularly-
bound TLCK to the inhibitory process is currently
being investigated by protection experiments using
lectins as reversible ligands of the NK cell surface.
The growth of human AML cells as solid tumours in
immune-deprived mice
R.D. Clutterbuck, C. Hills, P. Hoey, V. Shepherd,
R. Powles, P. Alexander' & J.L. Millar
Institute ofCancer Research, Sutton, Surrey, 1CRC
Medical Oncology Unit, Southampton General
Hospital, Hants, UK.
Human AML cells from the blood of a series of
patients have been stored in liquid N2 and later
thawed and implanted subcutaneously into mice
immune-suppressed by thymectomy and total-body
irradiation. Solid tumours resulted from the
majority of these inoculi which grew to a maximum
size, dependent upon patient and size of inoculum,
and then spontaneously regressed. A second
inoculum of AML cells into animals with regressing
tumours also produced tumours and thus regression
cannot be accounted for on the basis of returning
immunity and may be related to maturation in vivo
similar to that seen in vitro. Treatment with human
GM-CSF derived from human placental
conditioned medium, or medium conditioned by
5637 bladder carcinoma cells, failed to influence
either the growth or disappearance of these
tumours. Preliminary results show that
mononuclear cells derived from normal human
bone marrow behave in a similar manner to AML
cells by producing local growth followed by
regression.
The effect of cell-to-cell interactions on heat
sensitivity of HT29 human tumour cells
J. Dobrucki & N.M. Bleehen
University Department and MRC Unit ofClinical
Oncology and Radiotherapeutics, Cambridge
CB2 2QH, UK.
The relation between cell-to-cell interactions and
cellular heat sensitivity has been investigated using
the HT29 human colonic adenocarcinoma cell line.
A comparison has been made between cells growing
under different culture conditions, as single cells or
as cells growing in close cell-to-cell contact. The
population of separated cells was obtained by using
the chelating agent EDTA. Cells dispersed with
EDTA resume logarithmic growth on a substratum
without any lag period. EDTA treatment was
found to have no effect on heat sensitivity. Cells
growing as small multicellular spheriods (5-8 cells,
diameter 20-35gm) floating in the medium
constituted the second population in the model
system. The damage caused by heat treatment was
measured using two different end-points, ability to
form colonies and growth delay of the heated cells.
The latter permits a direct comparison of the
damage which occurs within both compared cell
populations. It also avoids the need to disaggregate
the cells with dispersing agent after heat treatment.
The two cell populations exhibit differences in
their heat sensitivity to heat treatment at 43°C, for
up to 4h. The survival curves of both populations
differ in the width of the shoulder, but not in the
slope. Heating spheroids for 30min does not effect
the survival. The same treatment reduces the
surviving fraction of single cells to the level of 85%.
The growth delay is longer for single cells than for
spheroids by a factor of 1.4. This difference is
constant for heating times between 1 and 4h at
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Sister chromatid exchange frequency in the
lymphocytes of patients having therapy for Hodgkin's
disease
T. Brown, A.A. Dawson & J.L. Watt
Departments ofMedical Genetics and Medicine,
University ofAberdeen, UK.
The method of harlequin staining at 2nd cell
division in vitro, was used to demonstrate sister
chromatid exchanges (SCE) in peripheral
lymphocytes of patients undergoing firstline
treatment for Hodgkin's disease.
The method provides a highly sensitive indicator
of induced genetic alteration at the DNA level and
various cytotoxic drugs, especially the alkylating
agents, have been shown previously to increase SCE
frequency. The pattern of elevation has not
previously been followed throughout and after a
course of standard chemotherapy, such as is used in
Hodgkin's disease. t'IE frequency was followed in
20 patients with newly-diagnosed Hodgkin's
disease, 11 having MVPP chemotherapy and 9
mantle radiotherapy. A characteristic pattern of
response to chemotherapy was found, with a
dramatic rise until about the 20th week of therapy,
with a fall before the end of the course. With
radiotherapy there is a small but sustained
reduction in SCE frequency. Thirty-two Hodgkin's
disease patients, who had had MVPP 2-12 years
previously, were also studied, and their SCE
frequency had reverted to normal.
The findings may have considerable significance
with regard to short-term response and long-term
prognosis.
High dose melphalan (HDM) in multiple myeloma
P. Selby, R. Powles, B. Robinson, M. Vincent &
T.J. McElwain
Royal Marsden Hospital, Downs Road, Sutton,
Surrey, UK.
Eighteen patients aged <60 years with multiple
myeloma have been treated with melphalan
140mgm-21.V. (McElwain & Powles 1983, Lancet,
1983, ii 822). All developed severe leucopenia and
thrombocytopenia and needed intensive support.
Among previously untreated patients 2/9 are too
early to assess, 6/9 recovered well taking a median
28 days (25-33) to restore leucocyte counts to
1091-1. All had moderate nausea and vomiting for
24-48h, mild diarrhoea and alopecia. One patient
died 16 days after HDM of intractable pulmonary
oedema probably because a rapidly falling
paraprotein reduced his oncotic pressure. Among
the 6 assessable patients 3/6 cleared their bone
marrows of myeloma and 3/5 who secreted
paraproteins remitted completely biochemically.
One patient who had entered a stable partial
remission on treatment with cyclophosphamide,
completely remitted with HDM. Eight patients had
relapsed or failed to respond to extensive previous
chemotherapy including oral melphalan. Median
time to 1091-1 leucocytes was 48 days (23-56) in 5
patients who had numerous infections. One patient
is too early to assess but two died, (cerebral
haemorrhage day 20; chest infection day 45). One
patient had a complete biochemical and marrow
remission for 5 months but subsequently relapsed
and died. In 4 others the paraprotein levels fell but
one rapidly relapsed and died, one died in
remission of a fungal infection, and two are alive in
partial remission. HDM is promising for untreated
myeloma patients under 60 years. Intensive
supportive care is required. Patients who are
resistant to low dose treatment may respond, but
toxicity is more severe and they may benefit less.
High dose ifosfamide and mesna after adriamycin
VP16213 and vincristine (VP-AV) for small cell lung
cancer
B.M.J. Cantwell, A.L. Harris, J. Bozzino, P. Corris,
S. Nariman, S. Pearce, J. Gibson, D. Hendrick, A.
Lishman, A. Hendrick & R. Leonard
Department ofClinical Oncology, Newcastle General
Hospital, Newcastle upon Tyne, NE4 6BE, UK.
The role of high dose ifosfamide in small cell lung
cancer (SCLC) has been evaluated in a crossover
study. 39 patients with SCLC have
been treated with adriamycin 40mgm -2 i.V.,
vincristine 2mg i.v., VP16213 100mgm-2 i.v., all
on day 1 and VP16213 200mgm-2 orally days 2
and 3 every 3 weeks for 3 courses. Patients with
limited disease who had a partial or complete
response had radiotherapy to the mediastinum and
primary lesion (24Gy, 4 fractions, 8 days) starting
3 days after course 3. Consolidation therapy with 2
courses of ifosfamide 5gm2 and mesna 5gm-2 by
24h infusion was given 3-weekly x 2. All treatment
was finished by week 12 from start of therapy.
Patients with extensive disease with response to VP-
AV crossed over to high dose ifosfamide for 3
courses. Patients who did not respond to VP-AV
after 2 courses crossed over to 3 courses of high
dose ifosfamide, 3-weekly. Overall responses to248 PROCEEDINGS OF BACR 25TH AGM
treatment regimen: 13/22 patients with limited
disease had CR, 7/22 PR (91% response rate); 17
patients had extensive disease, 2 had CR, 9 PR
(65% response). On crossover to ifosfamide 4/7
patients with limited disease not showing PR or CR
to VP-AV, showed subsequent response. 3/7
patients with extensive disease and PR to VP-AV
had further response to ifosfamide (50% 2nd line
response rate). There were 4 episodes of septicaemia
on VP-AV, (3 associated with radiotherapy). In 61
courses of ifosfamide and mesna only 1 episode of
neutropenia occurred. High dose ifosfamide is an
effective, relatively marrow-sparing agent in SCLC
and should be assessed as first line treatment. Short
courses of chemotherapy can be integrated with
radiotherapy and produce a high response rate with
a low incidence of serious toxicity.
N-acetylglucoseaminidase was measured all showed
significant, transitory elevation. Myelosuppression
was not marked - leukopenia grade 2 in three
patients: grade 3 in one; thrombocytopenia grade
3 in one. Hepatotoxicity was not observed.
TNO-6 has minimal activity in gastric cancer.
The unpredictable nephrotoxicity of this agent
reported by other workers has led to its withdrawal
by the manufacturers, Bristol Myers, from further
phase II studies.
Cis-dichlorodiammineplatinum (cisplatinum) and
etoposide (VP16):] [An effective salvage regimen in
malignant lymphoma
Phase II study of cis-1,1-diamino-methylcyclohexane
sulphate platinum (TNO-6) in gastric and colo-rectal
adenocarcinoma
D. Cunningham, M. Soukop, N.L. Gilchrist, G.J.
Forrest, C.S. McArdle, D.C. Carter, J.W. Dobbie,
M. Smith, S.B. Kaye & K.C. Calman
Royal Infirmary and Gartnavel General Hospital,
Glasgow, UK.
Cis-platinum has activity in gastric cancer. We have
evaluated the activity of its analogue TNO-6 in
gastric and colorectal adenocarcinoma. Twenty two
patients entered the study. All had histologically
proven disease. Sixteen patients had gastric cancer,
six of whom had received previous chemotherapy
with F.A.M., and six colorectal cancer three of
whom had received previous 5-fluorouracil. All
patients had measurable disease. TNO-6 30mg m-2
every 4 weeks was administered as an i.v. bolus in
16 patients, but was combined with hyperhydration
in the final six patients entering study as
nephrotoxicity was reported by other workers. No
responses were seen in colorectal cancer. In the
gastric cancer group, one patient had a partial
response, two had stable disease and 13 progressive
disease. Moderate nausea and vomiting occurred in
12 patients and alopecia in one. Creatinine
clearance was unaffected by chemotherapy, though
in six patients in whom the renal tubular enzyme
I.R. Judson & E. Wiltshaw
Department ofBiochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey and Royal
Marsden Hospital, London, UK.
Twenty five patients with non-Hodgkin's
lymphoma (NHL) unresponsive to standard
combination chemotherapy were treated with
cisplatinum 50mgm-2 i.v. x 1, plus VP 16
lOOmgm-2 i.v. daily x3q. 3wks. An average of 3
courses were given. All patients were heavily pre-
treated: 66% had received prior radiotherapy plus
chemotherapy, 28% three or more different drug
regimens. Seventeen patients were evaluable for
response. There were 5 complete remissions (CR)
29%, and 4 partial remissions (PR) 24%, giving an
overall response rate of 53%. The median response
duration for CR was 12wks. Median survival for
patients in CR was 25wks compared with only
5wks for non-responders. Toxicity included nausea
and vomiting, alopecia, minor renal impairment
and myelosuppression. This was occasionally
severe; wbc< 1,000 mm-3 3 patients (18%),
platelets <50,000 5 patients (29%). There was one
treatment-related death in a patient with bone
marrow infiltration. The response rate for
cisplatinum plus VP 16 is superior to that reported
for either single agent (PR only 26% and 30%
resp.) and the role of this combination in the
primary treatment of poor prognosis NHL is being
explored.PROCEEDINGS OF BACR 25TH AGM 249
Weekly alternating chemotherapy followed by
radiotherapy for small cell carcinoma of the bronchus
(SCCB)
S.M. Crawford', D. Parker3, M.G. Glaser2, B.R.
Southcott2 & E.S. Newlands1
1Departments ofMedical Oncology and
2Radiotherapy, Charing Cross Hospital, London W6
8RF and 3Bradford Royal Infimary, West Yorkshire
BD9 6RJ, UK.
Whilst high response rates to chemotherapy are
readily obtained in SCCB, the survival of these
patients remains poor. We have employed a
schedule of chemotherapy of short duration
followed by radiotherapy to sites of bulk disease.
The aims of this approach were to assess the
effectiveness of this schedule and to maximise the
time the patient enjoys off treatment. The schedule
is:
Course A: Etoposide 200mgm-2
Methotrexate 50mgm-2
Vincristine 1.4mgm-2(max. 2mg)
Course B: Adriamycin 20mgm-2
Cyclophosphamide 400mgm2
Course A and B alternating weekly for eight weeks.
5000cGy were then given to sites of bulk disease as
appropriate.
As at 1st December 1983, twenty four patients
have been entered. Toxicity has been very
acceptable to the majority of patients. Median
survival in the unstratified group on 1st December
1983, was forty weeks.
Pending the advent of treatment able radically to
improve the outlook in this disease, this strategy of
short duration treatment seems to offer the patient
a greater prospect of survival off treatment.
The prognostic significance of laboratory parameters
and performance status at diagnosis for survival in
small cell lung cancer
R.L. Souhami, I. Bradbury & S.G. Spiro
University College Hospital, Gower Street. London
WCJ, UK.
Previous studies have shown that performance
status (PS) and disease extent (limited or extensive
disease) are the most useful prognostic parameters
in small cell lung cancer (SCLC). We have assessed
the prognostic impact of these and other
measurements made at diagnosis in 370 patients
with SCLC entered into a randomised trial
assessing the effect of radiotherapy (RT) to the
primary tumour and mediastinum in addition to 12
courses of cyclical chemotherapy. The effect of the
addition of RT to survival was negligible. The
following parameters were individually significantly
related to survival at P<0.01: Disease extent, PS,
albumin (Alb; <39 vs >40gI -1), sodium
(Na; , 135 vs> 135yimol1 1), alkaline phosphatase
(AP; ( 1.5 x upper normal limit>), y glutamyl
transferase (<0.-28 vs>29 IU-1). Two step-wise
multiple regression analyses both showed that only
PS, Alb, Na, AP and disease extent each added
significantly to prognosis. The best prognostic
group (63 patients) with Alb >40gl-i,
Na.>136Yumo1l 1, Ap<1.5xupper normal limits
and PS.7 Karnofsky comprised 35 patients with
limited disease and 25 extensive disease had a
median survival in excess of that of the 127 limited
disease patients in the entire study. It appears
possible to select different prognostic groups at
diagnosis on the basis of simple laboratory
parameters (Alb, Na, AP) and PS. These variables
offer as good a stratification of disease prognosis as
disease extent, which usually includes more
numerous and invasive tests.
Extracellular ATP induces ion fluxes and inhibits cell
growth of murine erythroleukemia cells
S.B. Chahwala & L.C. Cantley
CRC Experimental Chemotherapy Group,
Department ofPharmacy, University ofAston,
Birmingham B4 7ET U.K. and Department of
Biochemistry and Molecular Biology, Harvard
University, Massachusetts, USA.
Changes in ion flux across the plasma membrane
play a pivotal role in the regulation of proliferation
and differentiation. Exogenous ATP has been
shown to cause a profound increase in the
permeability of the plasma membrane to certain
ions and to selectively inhibit the growth of
transformed cells. The mechanism of these effects is
not known. We have attempted to characterise
more fully the nature of the ATP-induced changes
in ion flux using Friend virus-infected murine
erythroleukemia cells (MEL), and to study the
effect of ATP on their growth and differentiation.
ATP (1 mM) inhibited MEL cell growth with an
increase in doubling time but did not bring about
differentiation as measured by benzidine staining. It
also had no effect on DMSO-induced250 PROCEEDINGS OF BACR 25TH AGM
differentiation of MEL cells. ATP (1 mM)
coincubated with 45Ca2+ stimulated the initial rate
of Ca2+ exchange from a basal level of 5
pmoles min-' to 18pmolesmin-110-6 cells to
achieve a twofold increase in steady-state (Ca2+) as
measured by isotopic equilibration. Ca2+ influx was
blocked by DIDS, an inhibitor of anion transport.
Ca2+ was cotransported with Cl- anion resulting in
an electroneutral flux, the ratio of ATP stimulated
Cl - to Ca2+ uptake being 1.6:1. K+ and Na+
influx were also stimulated, the Na+ influx
dissipating the Na+ gradient and thus inhibiting
nutrient uptake. Na+ influx and Ca2+ influx
occurred by separate independent routes, since Na+
influx was not inhibited by DIDS. The effects
observed were specific for ATP
(KmMgATP=0.93mM), since AMP, GTP,
adenosine and slowly hydrolysable ATP analogue
AMP-PNP were without effect. These ATP-induced
changes in ion flux are considered to be responsible
for growth inhibition and may form the basis for
therapeutic intervention.
however, the reverse was true with greatest cell
killing occuring deeper in the spheroid. Selective
disaggregation of spheroids before drug treatment
showed only small differences in the intrinsic
response of the sub-populations to CCNU, hence
confirming the dependence of the effect upon
spheroid structure. Uptake of 14C-labelled CCNU
by cells in different layers within spheroids is
currently being measured. Spheroids have also been
grown from human small cell and large cell
anaplastic lung cancer with different cell packing
and inter-cellular contact characteristics. Isolation
of sub-populations of cells from these spheroids has
been achieved using Percoll gradients and cell
sorting with the vital stain Hoechst 33342.
Use of an isotope uptake assay for predictive
quantitation of lung tumour response
G. Walls, N. Fox & P. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
An investigation of the relationship between tumour
geometry and cytotoxic drug response using an in
vitro tumour model
T.T. Kwok & P. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
We are using multicellular tumour spheroids to
investigate the relationship between factors
determined by tumour geometry and the response
of cells within solid tumours to cytoxic drugs. In
addition to the question of drug diffusion, it is
known that gradients of pH, oxygenation and
proliferative status exist within spheroids and these
appear likely to influence drug response. Spheroids
of the EMT6/VJAC mouse tumour cell line have
been grown to a diameter of 800,u and then
bacterial neutral protease has been used to
successively "strip" 4 sub-populations of cells from
the surface. These sub-populations have been
characterized in terms of 3HTdR labelling index,
cell cycle distribution, RNA contents, cell size and
clonogenic capacity. Cells from the outer layers
were larger and proliferating more rapidly than
cells deeper within the spheroids. The plating
efficiencies of cells from all sub-populations were
similar. When spheroids were treated with
adriamycin or with nitrogen mustard (HN2) for 1 h
before disaggregation, killing of clonogenic cells
was greatest in the outer layer with reduced killing
towards the centre of the spheroid. For CCNU,
Isotope uptake assays have many potential
advantages over clonogenic assays for predictive
testing of human tumour response. Among these
are no requirenent for an absolutely single cell
suspension, the totally objective nature of the data
produced and the speed of obtaining the result. A
recently described tritiated thymidine (3HTdR)
uptake assay (Friedman & Glaubiger, 1982, Cancer
Res., 42, 4683) apparently overcomes the principal
problem of such assays i.e. the contribution of
normal tissue elements in the tumour to isotope
uptake, by plating the tumour cells into dishes
containing an agar base. Experiments have been
carried out to measure the response of human small
cell lung cancer (SCLC) xenografts by both a
simplified version of this 3HTdR uptake assay and
the "Courtenay" soft-agar cloning assay. Excellent
agreement was found between the two assays in
measurement of response to radiation and a range
of cytotoxic drugs over 3 decades of cell kill.
Radiation response curves for recently established
cultures of human SCLC cells have been obtained
using the isotope assay and were found to fall
exponentially with no initial shoulder. The
radiation response of a mouse tumour cell line
however, showed an initial shoulder in both assay
systems. Although normal human bone marrow
cells do take up some 3HTdR, the amount is
relatively small in comparison with SCLC cells. It is
hoped that the isotope uptake method may be
useful as a rapid predictive assay of tumour
response using bone marrow and node biopsy
specimens from patients with SCLC.PROCEEDINGS OF BACR 25TH AGM 251
Drug sensitivity of human glioma cells in culture -
the effects of verapamil
S. Merry, S.B. Kaye & R.I. Freshney
Department ofClinical Oncology, University of
Glasgow, Glasgow G12 9LX, UK.
In previous studies we have identified one human
glioma cell line sensitive to adriamycin (G-MCF)
and two human glioma cell lines which are resistant
to this drug (G-UVW and G-CCM). Our
investigations of the intracellular accumulation of
adriamycin in these cell lines have shown that both
energy deprivation and the addition of verapamil
are able to increase intracellular drug concentration
by at least 100% in the resistant cell lines, but not
in the sensitive cell line.
We now present data showing that similar doses
of verapamil are able to increase significantly the
cytotoxicity of adriamycin in the resistant cell lines.
Cells were seeded into 24-well plates and, after 72h,
were exposed to adriamycin or adriamycin plus
verapamil for a further 72h followed by a recovery
period of 120h. Cell number at the end of this
period was determined by trypsinisation and
Coulter counting of the resultant single cell
suspension. A decrease in the adriamycin ID50 of at
least 5-fold for the two resistant cell lines was
observed upon the addition of verapamil with
growth inhibition increased from 25% to 75% for
G-CCM at 7 x 10-8M adriamycin and from 50%
to 90% for G-UVW at 3 x 10-8M adriamycin.
Further studies using other drugs are in progress.
These data suggest that for human tumour cells
adriamycin resistance is related to differences in
drug transport as has been demonstrated in animal
models. Furthermore, a potential role for verapamil
in circumventing the tumour cell resistance
observed clinically is suggested.
Structure-antitumour activity relationships in
N-alkylformamide derivatives
M.D. Threadgill, E.N. Gate, S.P. Langdon &
M.F.G. Stevens
Cancer Research Campaign Experimental
Chemotherapy Group, Department ofPharmacy,
University ofAston in Birmingham, Birmingham B4
7ET, UK.
A series of N-alkylformamide derivatives of general
formula R3C(X)NR1R2 has been prepared where
R'=H, Me, CD3, CH2CF3, CH2CH2,Cl,
cyclopropyl, CH2OH, CH2OEt, CH2OAe, Ch2OBz,
CH2NMe2; R2=H, Me, CF31 CCl3+ R3=H, Ph,
NHMe, NMe2 and X=O, S, NH.
These compounds have been tested for activity
against the M5076 ovarian sarcoma and the TLX5
lymphoma in vivo in mice. Against both tumours,
N-methylformamide R1 =Me, R2=R3=H, X=O;
NMF) was by far the most potent agent of the
group. A putative metabolite of NMF, N-(hydroxy-
methyl)-formamide (R1 =CH2OH, R2=R3=H,
X=0) had, at most, marginal activity in these
tests. In this series, it appears that an N-methyl
group is a strong requirement and the formyl group
is a lesser requirement for activity.
Experimental antitumour activity and mechanism of
action of the novel anticancer agent CCRG 81010
P. Workman & F.Y.F. Lee
MRC Clinical Oncology and Radiotherapeutics Unit,
Cambridge CB2 2QH, UK.
CCRG 81010 (8-carbamyl-3(2-chloroethyl)-
imidazo(5,1-d)-1,2,3,5-,-tetrazin-4(3H)-one; M and
B 39565, NSC 353451) is a novel antitumour agent
with broad spectrum activity in standard preclinical
screens (Stevens et al., 1983, Br. J. Cancer, 48, 120)
and is currently undergoing phase 1 trial. We have
determined the effect of CCRG 81010 against
several syngeneic mouse tumours and human
tumour xenografts, in direct comparison with
certain nitrosoureas and the imidazole triazene
DTIC, to which it exhibits structural similarities.
Tumours were grown i.m. in the legs of C3H
(mouse tumours) or MFI nude (xenograft) mice.
Mice received single i.p. doses of drugs when
tumours reached 8-10mm diameter, and growth
delay (GD) was used as the end-point. A linear
dose-response to CCRG 81010 was seen in the
KHT mouse sarcoma with 50mgkg-1 (0.6 x LD50)
producing GDs of 12-17 days. Equitoxic doses of
CCNU, methyl-CCNU and BCNU gave similar
GDs, though chlorozotocin was less active (GD-7
days). In the KHT variant made resistant to
nitrosoureas CCRG 81010 gave GDs of only 2-5
days similar to those in the intrinsically resistant
RIF-1 mouse sarcoma. DTIC was equally inactive
against all 3 mouse tumours. Cyclophosphamide
showed comparable activity in KHT and RIF-l but
reduced activity in the KHT resistant tumour.
Phenobarbitone pretreatment reduced the activity
of CCRG 81010 against the KHT tumour, whereas
SKF525A and misonidazole were without effect. In
human xenografts CCRG 81010 was similar to
CCNU: Both were inactive against the colon252 PROCEEDINGS OF BACR 25TH AGM
carcinoma HT29 and the large cell lung tumour
L23, but very effective against the small cell lung
carcinoma H69. To summarise, CCRG81010 has a
spectrum of antitumour activity similar to that of
CCNU but different to that of DTIC and
cyclophosphamide.
Low dose aminoglutethimide for advanced
postmenopausal breast cancer
B.M.J. Cantwell, R. Sainsbury, A.L. Harris, R.G.
Wilson, J. Farndon, P. Dawes, R.G.B. Evans & M.
Dowsett
Departments ofClinical Oncology, Radiotherapy and
Surgery, University ofNewcastle upon Tyne, UK.
Aminoglutethimide (AG) 125mg twice daily is as
effective as 250mg 4 times daily in producing
oestrone and oestrodiol suppression (Harris et al.,
1983, Br. J. Cancer, 47, 621). Since the higher dose
is an effective endocrine therapy we clinically
assessed low dose AG. Doses used were 125mg
twice daily plus hydrocortisone (HC) 20mg twice
daily to treat advanced postmenopausal breast
cancer. So far 38 patients with advanced
progressive breast cancer have been entered into
study and 30 patients followed for 3 months or
longer. The response to AG+HC by U.I.C.C.
criteria assessed after 3 months is 1 complete
response (8 months+duration) 7 partial responses
(4,4+, 6,7,7,7+ and 11+ months duration). Nine
patients have achieved stable disease (SD)
(4,4+,5+,6,6,7+,7+,7+ and 7+ months
duration). This gives an overall objective response
rate of 27% (8/30). Mean age in responders
(objective and stable disease combined) was 60.9
years and was 62.3 years in non-responders. There
was no significant difference in age, years after
menopause, disease free interval, weight and
predominant sites of disease at start of AG+HC
therapy. In 12 patients who did not respond to
Tamoxifen before AG+HC therapy, there were 3
(1 PR, 2SD) who subsequently responded to low
dose AG+HC. In 6 patients who had a prior
response to Tamoxifen therapy there were 3 (2PR,
1 SD) subsequent responses to low dose AG+ HC.
Toxicity with low dose AG+HC was considerably
less than previous experience with higher doses
(Harris et al., 1983, Eur. J. Cancer Clin. Oncol., 19,
11), nausea and vomiting occurring in 3% of
patients on the low dose schedule versus 15% with
higher dose AG (rash incidence was the same in
both low and higher dose groups). Low dose AG
produced an objective response rate comparable to
conventional dose with considerably less toxicity.
A comparison of two doses of trilostane combined
with dexamethasone in metastatic breast cancer
A.C. Hindley', P.M. Wilkson', J. St. John', C.G.
Beardwell3 & G.G. Ribeiro2
'Departments ofClinical Pharmacology,
2Endocrinology and 3Radiotherapy, Christie
Hospital, Manchester, UK.
Trilostane (T) a steroid agent, is an inhibitor of
adrenal enzymes in the rat. We have shown that a
combination of (T) 240mgqds and Dexamethasone
0.5mgbd induce remission in metastatic breast
cancer (Beardwell et al., 1983, Cancer Chemother
Pharmacol., 10, 158). The principle hormonal
changes occurring in those patients on (T) alone,
were significantly elevated serum concentrations of
170H pregnenolone, dehydroepiandrosterone
sulphate and androstenedoine, with significantly
reduced levels of oestrone. After the addition of
Dexamethasone, levels of these hormones returned
to baseline, with the exception of oestrone, which
remained depressed. The response in all patients
receiving therapy for >eight weeks was 10/31 PR
(32%) and 3/31 (10%) stable disease by UICC
criteria. Gastrointestinal side effects were common,
vomiting occurring in (24%) and diarrhoea in (11%)
and therapy was withdrawn in (18%). Nineteen
patients subsequently received (T) 120mgqds with
Dexamethasone 0.5mgbd. The incidence of side
effects were greatly reduced, but an objective
response was observed in only one patient which
suggests that the lower dose may be ineffective,
although initial results suggest that the hormonal
effects on (T) alone are similar for both doses. The
mechanism of action of the combination is
presently undefined, but the differences in response
with the two doses of (T) suggests that the anti-
tumour is not due to Dexamethasone alone.
Further studies are in progress to determine the
optimum dose and frequency of administration.
Pharmacokinetics and metabolism of mitoxantrone
J.S. Macpherson, J.F. Smyth, J.A. Clements',
M.W. Ramsay, P.S. Warrington, R.C.F. Leonard &
C.R. Wolf
Imperial Cancer Research Fund, Medical Oncology
Unit, Western General Hospital, 'Department of
Pharmacology, Heriot-Watt University, Edinburgh,
UK.
Mitoxantrone (M) is an anthraquinone derivative
which we are currently evaluating for the treatmentPROCEEDINGS OF BACR 25TH AGM 253
of breast cancer. We have established the following
HPLC assay to determine M concentrations in
plasma and urine. Plasma or urine samples were
applied directly to a pre-wet C18 Sep-Pak cartridge,
washed with 10mM HCl and the sample eluted with
100% methanol. The recovery of M for both
plasma and urine samples was almost 100%. The
sample was then evaporated to dryness and
reconstituted in the HPLC running buffer of
ammonium formate/acetonitrile 73:27 (ph4.3). M
was then separated on a i Bondapak C18 column
and drug concentration monitored at 658nm. The
detection limit was 1 ngml-1 plasma. Evaluation of
the data obtained so far from 6 patients showed the
plasma clearance follows 3 phases, with TI values
of oc=10.7+2.2min, f=2.0+0.5h and y of
17.0+5.7h. Urinary excretion of M in the first 24h
was 3.0+ 1.6% of the dose. In addition to
unchanged drug, 2 metabolites were detected. UV-
Vis spectra indicated that both contained an intact
anthraquinone nucleus. The retention time of these
products was not altered on incubation with fi-
glucuronidase or sulphatase suggesting the presence
of either primary oxidation products or conjugates
other than glucuronide or sulphate. In contrast to
this finding initial experiments in vitro using rat
liver fractions showed 2 primary metabolites to be
formed. Both of these products had different
retention times on HPLC to the metabolites found
in the urine. The formation of one of these
products was dependent on the presence of the
cofactor required for glucuronidation (UDPGA).
The second major product required the presence of
cytosolic enzymes. If these products are found in
man it would appear that they are either further
catabolised or excreted in the bile.
Controlled trial of adjuvant chemotherapy with
cyclophosphamide methotrexate and fluorouracil
(CMF) for breast cancer
A. Howell, H. Bush, W.D. George, J.M.T. Howat,
D. Crowther, R.A. Sellwood, R.D. Rubens, J.L.
Hayward, R.D. Bulbrook, I.S. Fentiman & M.
Chaudary
Departments ofMedical Oncology and Surgery,
University Hospital ofSouth Manchester and Guy's
Hospital, London, UK.
In 1976 Bonadonna et al. (NEJM, 294, 405)
reported that adjuvant CMF prolonged the relapse
free survival in patients with positive axillary nodes.
It was decided to repeat this study in Manchester
starting in March 1976 and at Guy's Hospital
starting in October 1979. In each centre patients
with operable breast cancer (TO-3,NO,1,MO) were
treated with total mastectomy and complete axillary
clearance. Patients with involved axillary lymph
nodes aged <70 years were allocated randomly to
either no additional treatment (n= 162) or 12
monthly cycles of CMF (n= 165). Each cycle
consisted of cyclophosphamide 80mgm 2 p.o. on
days 1-14, methotrexate 32mgm 2 i.v. on days 1
and 8 and fluorouracil 480mgm-2 i.v. on days 1
and 8. There were no significant disparities in the
distribution of prognostic variables between
treatment and control groups. There was a highly
significant difference in relapse-free survival in
favour of CMF (P=0.005) after a median duration
of follow up of three years. Recurrence rates were
compared for subsets of the pooled data.
Significant differences between treated and control
patients were seen in those with 1-3 nodes involved
(P=0.04), >4 nodes (P=0.02) and also in
premenopausal patients (P=0.02) but not in
postmenopausal patients (P=0.13). There was no
significant difference in overall survival between the
two groups. Side effects were common and included
nausea and vomiting (65%), myelosuppression
(70%) and alopecia (20%).
We conclude that CMF significantly delays
recurrence but, at least, early in the follow up
period has no effect upon survival.
Epidermal growth factor and oestrogen receptors in
human breast cancers
J.R.C. Sainsbury, J.R. Farndon & A.L. Harris
Departments ofSurgery and Clinical Oncology,
University ofNewcastle upon Tyne, Newcastle upon
Tyne, UK.
Epidermal growth factor (EGF) is a mitogen for
many tissues and its effects on cultured breast cells
include stimulation of DNA synthesis. Receptors
for EGF have been described on human derived
cell lines such as MCF7 and A431. EGF was as
potent as oestrogen in causing cell growth.
Oestrogen receptors (ER) have been found in 50-
65% of breast cancers and are of predictive value
in survival and response to therapy.
The aim of this study was to detect and quantify
EGF receptors on breast cancer specimens and to
compare this to ER status. Biopsies were taken
fresh, collected on ice and a membrane pellet
prepared by a differential centrifugation technique
using a TRIS-NaCl-BSA buffer. Receptors were
identified by a competitive binding method using
0.6nmol I1 1251-EGF incubated with varying
concentrations (0.025-500nmol1-1) of cold EGF.
Nuclear and cytosolic ER were measured by a254 PROCEEDINGS OF BACR 25TH AGM
dextran-coated charcoal technique. High affinity
EGF receptors were detected with a Kd of 0.7-
1.5 x 10-9M 33 primary breast cancers have been
studied. Nineteen were ER+ve (57%), 6 (18%)
were EGF+ve, 4 of these were ER-ve and
2 ER+ve. Five out of six metastatic lymph nodes
studied were EGF+ve and 1 EGF-ve: all were
ER-ve.Theadditionofanti-proteolyticagentsdidnot
affect the results.
These results show that some human breast
tumours express EGF receptors. The negative
correlation with ER status suggests that these
tumours may have a poorer prognosis. Since EGF
stimulates anchorage independant growth the
higher incidence of EGF positive tumours
(P<0.001, Fisher's exact test) in lymph nodes
suggest that EGF may have a role in metastasis.
responses to other elements of the combination.
Clear relationships were observed between cis-
platinum resistance in vitro in untreated patients
and a failure to respond to other chemotherapy.
Cis-platinum and adriamycin sensitivity in vitro
were clearly related to clinical outcome, but no
relationship exists between such sensitivities and
response to other chemotherapy.
A bis-benzimidazole probe for chromatin structure
and cellular sensitivity to DNA damage
P.J. Smith & J.V. Watson
Clinical correlations in ovarian cancer using the
clonogenic assay
A.P. Simmonds & E.C. McDonald
Cell Laboratory, Biochemistry, Royal Maternity
Hospital and Royal Infirmary, Glasgow, UK.
Culture of ovarian tumour material has been
continued as previously described (Simmonds &
McDonald, 1982, Br. J. Cancer, 46, 462) using 200
samples from 106 patients in the Glasgow area.
Drugs tested were cis-platinum and adriamycin
using the parameters for sensitivity of Alberts,
Salmon et al., 1980. Lancet, 340). Clinical follow-up
was achieved courtesy of the West of Scotland
Clinical Trials Unit, Department of Oncology and
consultant staff in the gynaecology and oncology
departments of the hospitals involved. Results
obtained in the laboratory were then compared
with clinical outcome. Of the 57 patients
represented by the 71 samples available for drug
study, only 48 received chemotherapy, of whom 23
received the drugs of test. 10/11 patients judged
sensitive to cis-platinum received it in some form,
with 7 partial and 3 complete responses. 5/6
patients sensitive to adriamycin received it and had
a good response. Equivocal results were obtained
with patients with intermediate responses to cis-
platinum, even in those with known sensitivity to
adriamycin. Five of 6 patients resistant to cis-
platinum received it. Three were also resistant to
adriamycin and have failed to respond to CAP
chemotherapy. Two patients with complete
responses to the CAP regime had unknown
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Cambridge CB2 2QH, UK.
Transcriptionally active or potentially active regions
of chromatin demonstrate enhanced sensitivity or
accessibility to endonucleases. They also provide
preferred sites for the direct or enzyme-mediated
effects, on DNA, of various agents used in tumour
therapy: e.g. bleomycin, ionising radiation,
nitrosoureas and actinomycin D. We have
investigated whether cellular responses to DNA
damage can be related to this feature of chromatin
in intact human cells by using a DNA-specific
ligand (Hoechst 33342) as a vital-probe for
chromatin structure. The appearance of ligand-
induced DNA strand-breaks was related to
Ho33342 uptake (measured by flow cytometry).
However, compared with radiogenic DNA strand-
breaks, Ho33342-associated damage disappeared
slowly. The endonuclease (DNase II) sensitivity of
nuclear DNA in permeabilised cells correlated with
the distribution and level of ligand-induced DNA
strand-breakage. Cellular responses (lethality and
the retention of cells in G2 phase) to DNA damage
induced by either the ligand or a broadspectrum
DNA damaging agent (X-radiation) could be
ascribed to the degree of expression of enzyme-
sensitive targets in chromatin. Enhanced target
expression was found in cells derived from a patient
with the cancer-prone, radiation-hypersensitivity
disorder ataxia telangiectasia. Our studies provide
some insight into the laboratory hallmarks presented
by the disorder ataxia telangiectasia and indicate
how the biological responses of a given tumour cell
type to therapy-induced DNA damage may be
ascribed and perhaps predicted from studies on
chromatin structure and organization using ligand
or enzymatic probes.PROCEEDINGS OF BACR 25TH AGM 255
Precise epitope mapping of mouse tumour-associated
protein p53
A. Wade-Evans & J.R. Jenkins
Marie Curie Research Institute, The Chart, Oxted,
Surrey, UK.
p53 is a cellular-encoded, transformation related
protein, present at elevated levels in numerous
transformed cell lines (Linzer et al, 1979, Cell, 17,
43).
In order to study the function of p53 in detail, a
full length cDNA clone has been isolated in this
laboratory (Jenkins et al., manuscript in
preparation). Using appropriate recombinant DNA
techniques the coding region of the p53 clone has
been inserted into plasmid vectors, which direct in
vitro expression of the protein, both by itself, and
as a fusion protein with SV40 small t.
A combination of in vitro transcription,
translation in a cell-free reticulocyte lysate system,
immunoprecipitation using p53-specific monoclonal
antibodies, and Bal 31 deletions of the gene, have
enabled us to map accurately the epitopes of
several different monoclonal antibodies.
The resulting data have allowed us to construct
synthetic peptides, which are complimentary to the
corresponding antigenic sites on the p53 protein.
The combination of anti-p53 monoclonals together
with their complementary synthetic peptides is
being used as an immunochemical step in the
preparative isolation of p53 protein from genetically
engineered primate cell lines, expressing mouse p53
as high levels.
The epitope mapping data also provide insights
into the structural associations that p53 may adopt
in the cell.
Recombinant DNA directed expression of the
transformation-associated protein p53
J.R. Jenkins, K. Rudge, K. Barrett & A. Wade-
Evans
Marie Curie Research Institute, The Chart, Oxted,
Surrey, UK.
We have cloned full length cDNA sequences coding
for the murine transformation-associated protein
p53. Using appropriate recombinant DNA
techniques we have constructed expression vectors
which direct the efficient synthesis of murine p53
protein in eukaryotic systems. These expression
vectors are being used to investigate the
mechanisms of cellular localization of p53 and its
association with SV40 large T antigen in a variety
of normal and transformed cells.
Transforming activity of a celular proto-oncogene
after in vitro modification by a chemical carcinogen
D.H. Phillips, C.J. Marshall & K.H. Vousden
Institute ofCancer Research, Fulham Road, London
SW3 6JB, UK.
Activated transforming genes have been found in a
number of human tumour DNA's using the
NIH/3T3 transfection assay. In most cases the
genes detected are members of the cellular ras gene
family. The mechanism by which they have been
activated in tumour cells has been shown to be a
single point mutation resulting in the alteration of
an amino acid in the p21 protein product. We have
investigated the effect of modifying the normal
cellular c-Ha-ras-1 gene by treatment with (±)anti-
7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo-
(a)pyrene (BPDE). pEC, a plasmid containing an
insert that carries the c-Ha-ras-l gene, in 10mM
tris-HCl, ImMEDTA, ph7.4 (O.5 gjl-l) was
treated with various concentrations of BPDE in
EtOH (0.5vol) at 370 for 2 hours. DNA was
purified from the reaction mixture, calcium-
phosphate precipitated and used in an NIH/3T3
transfection assay (200-1000ng/plate). After 2
weeks the plates were scored for transformed foci.
From DNA treated with BPDE at a ratio of 15:1,
1.7-2.3foci/pg DNA were observed. Transformed
foci were picked and the DNA isolated from them
was used in a second round of transfection into
NIH/3T3 cells. DNA isolated from the secondary
transformants was subjected to Southern blot
analysis using a variety of restriction enzymes. Four
transformation events have been analysed so far
and in one case an Msp I restriction site has been
altered. A change in sequence here is predicted to
lead to an alteration in the amino acid at position
12 of the gene product. These results demonstrate
that in vitro modification of a cellular proto-
oncogene with a chemical carcinogen can lead to an
active transforming gene. This provides direct
evidence that DNA is the primary target of
chemical carcinogen-mediated malignant
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Transforming genes in human malignant melanoma
R.A. Padua & N. Barrass
Marie Curie Research Institute, The Chart, Oxted,
Surrey, UK.
DNA, isolated from 7 surgical specimens of
malignant melanoma and 6 established cell lines,
was tested for its ability to transform NIH3T3
mouse fibroblasts by transfection. Positive results
were obtained from one of the primary tumour
DNAs and 3 of the cell lines. Human sequences
were identified in transformant DNAs by
hybridization with an Alu human repetitive
sequence clone. Cloned oncogene probes were used
to identify the genes activated in the transformants
obtained. An activated N-ras gene was identified in
one of the cell lines. In the case of the primary
tumour and two of the cell lines transformants were
obtained which showed no detectable homology to
the three known ras genes, or to any other probe in
a comprehensive oncogene library.
The SV40 transformed human breast epithelial fR
cell lines contain a deletion in their SV40 large T-
antigen
S.E. Chang
Marie Curie Research Institute, The Chart, Oxted,
Surrey, Jacqueline Keen and Joyce Taylor-
Papadimitriou, Imperial Cancer Research Fund,
Lincoln's Inn Fields, London, UK.
The availability of the fR series of SV40
transformed breast epithelial cell lines (Chang et al.,
1982, Cancer Res., 42, 2040) gives us a unique
opportunity to study how SV40 can be integrated
in the DNA of human epithelial cells. DNA
mapping experiments using restriction enzymes and
southern blot techniques show that one SV40
genome is integrated in these transformed cells and
that there is a deletion of up to 100 base pairs in
the region coding for large T-antigen. The sites of
integration and deletion are coincident and map in
the region 4000-4100. The NH2-terminal end of the
large T-antigen is intact, a finding consistant with
the idea that this region may be essential for
transformation (Colby & Shenk, 1982, PNAS, 79,
5189; Clayton et al., 1982, Nature, 299, 59).
Since K14, an SV40-transformed human
keratinocyte cell line (Taylor-Papadimitriou et al.,
1982, Cell Diff., 11, 169) also has a deletion in its
SV40 large T-antigen, it is possible that a casual
relationship exists between deletions in the large T-
antigen and the ability of SV40-transformed human
epithelial cells to survive "crisis" and to give rise to
immortal cell lines.
Monocytic cells in lymphomata
S. Matthews, A.J. Freemont, C.J.P. Jones & R.W.
Stoddart
Pathology Department, University ofManchester
Medical School, UK.
Cells apparently derived from the monocyte lineage
have been identified in lymphomata, but their
function remains obscure. Using immunocyto-
chemical, lectin binding and morphological criteria
we have attempted to characterise these cells more
fully. Paraffin embedded lymphomatous and
reactive lymph nodes have been examined for al-
anti-trypsin (oclat) and lysozyme, using polyclonal
antibodies, and sugar residues, using several lectins
including concanavalin A (conA) and wheat germ
agglutinin (WGA) by PAP, fluorescent lectin and
avidin-biotin peroxidase techniques. Two subgroups
of cells have been identified which, in lymphomata,
have distinctive distributions. The first consists of
rounded cells 15-20,um in diameter which react
strongly for lysosyme and ca1at and bind conA and
WGA avidly. They resemble blood monocytes and
cluster about nodules of both Hodgkins and non-
Hodgkins lymphomata. The larger cells in the
second subgroup have long cytoplasmic processes
embracing neighbouring cells, stain weakly for
lysozyme and ac,at and bind conA weakly. The role
of these groups is speculative. The first might be
either a primary response or one secondary to T
lymphocyte activation and either may be forcing a
nodular growth pattern on the tumour. The second
could represent either a response to the lymphoma
or recruitment of cells necessary for some aspect of
tumour behaviour. These, and other possibilities,
are being investigated.
Characterisation of mononuclear cell infiltrates, by
monoclonal antibodies, in colorectal carcinomas,
polyps and the adjacent normal bowel
D. Heineman, H.C. Umpleby, M.O. Symes &
R.C.N. Williamson
Department ofSurgery, University ofBristol,
Bristol, UK.
Serial frozen sections were prepared from a
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bowel in 10 patients and from a benign polyp in a
further 10 patients. Six of the patients with a polyp
had a concomitant carcinoma. The mononuclear
cell infiltrates were stained by the indirect
immunoperoxidase technique using a panel of
mouse monoclonal antibodies to human leucocyte
antigens. The degree of infiltration was graded 5
(heavy), 4 (moderate), 3 (few), 2 (occasional) and 1
(nil). Assessment was performed by two
independent observers.
The colorectal carcinomas and adjacent normal
bowel showed an equal degree of leucocyte
infiltration, graded 4-5 in 7 cases (Hele-4). In a
further patient infiltration was graded 3 in each
tissue. In 7 of the carcinomas cytotoxic/suppressor
T lymphocytes (UCHT-4) graded 3-4,
predominated over helper cells (OKT-4), graded 1-
2. By contrast in the adjacent normal bowel
cytotoxic and helper cells were present in equal
numbers, graded 2, in 7 patients. Of the 10 polyps
leucocyte infiltration was graded 5 in 9 and 4 in 1.
In 9 of the 10 polyps cytotoxic cells graded 3
predominated over helper cells graded 1-2. The
number of helper cells was equal in all 6
concomitant polyps and carcinomas. The similarity
in cell infiltrate between polyps and carcinomas is
in favour of the polyp carcinoma sequence
(Morson, 1974, Proc. R. Soc. Med., 67, 451) and
the predominance of cytotoxic cells in tumour
tissue accords with the association between
lymphocytic infiltration in a tumour and a
favourable prognosis (Hutchinson et al., 1983, J.
Exp. Clin. Cancer Res., 2, 161).
Immunoperoxidase staining of primary breast
tumours with an antibody against human milk fat
globule antigen predicts survival and response to
hormone therapy
M.J.S. Wilkinson, A. Howell, J. Taylor-
Papadimitriou, D. Barnes, R. Swindell & R.A.
Sellwood
Departments ofSurgery, Medical Oncology and
Clinical Research, Christie Hospital, Manchester and
Imperial Cancer Research Fund, Lincolns Inn Fields,
London WC2, UK.
There is a need for a simple procedure performed
on the primary tumour of patients with cancer of
the breast which give prognostic information. The
value of such a procedure would be increased if it
predicted response to endocrine therapy. We have
assessed the predictive value of the staining of
tumours with antibody raised against a component
of the milk fat globule membrane. (Arklie et al.,
1981, Int. J. Cancer, 28, 23). A monoclonal
antibody (HMFG-1) was raised against delipidated
human milk fat globule membranes and used to
stain 200 primary breast tumours by an indirect
immunoperoxidase technique. Several staining
patterns were seen but the presence or absence of
antigen in the spaces outside cells (ECS) was of
most prognostic importance. Of the 200 patients
studied 79 relapsed and 51 received endocrine
therapy, 41 were assessable for response of whom
41% responded. Patients whose tumours showed
ECS staining had a significantly longer relapse free
interval (P<0.008) and survival (P<0.002). 65% of
patients who relapsed and were ECS+ve responded
to hormone therapy whereas 33% of ECS-ve
responded. The median time to progression of all
patients with ECS staining tumours was 8 months
and 3 months for ECS-ve tumours. The figures
for progesterone receptor +ve and -ve patients
was 9 months and 3 months respectively.
We conclude that the presence of the milk fat
globule antigen, HMFG-1 outside the tumour cell
and presumably shed from the cell membrane is
related to a good prognosis and if the patient does
relapse the likelihood of response to endocrine
therapy is high and equivalent to that seen in
progesterone receptor-positive tumours.
Prediction of relapse free interval in patients with
malignant glioma using a chemosensitivity test
J.L. Darling, D.G.T. Thomas, G.P. Finn, R.I.
Freshney & E. Paul
Gough Cooper Department ofNeurological Surgery,
Institute ofNeurology, Queen Square, London WCJ
and Department ofClinical Oncology, Glasgow UK.
One hundred and seventeen patients with malignant
glioma (Kernohan grades III and IV) were treated
with adjuvant chemotherapy comprising
procarbazine (PCB) 50mg t.d.s. for ten days,
CCNU 80mg stat and vincristine (VCR)
1.4mgm-2 stat, following whole head irradiation
fractionated to a total dose of 4000-5000cGy. Cell
cultures were preprared from 40 patients in this
series and their sensitivity to each of the drugs was
assessed in a microtitration assay with 35S-
methionine incorporation as the end point.
Sensitivity to PCB or CCNU was linked with
increased relapse free interval (RFI) whilst
sensitivity to VCR was not. It was found that 22/40
(55%) of patients responded to PCB and/or CCNU
in the assay. The RFI of patients who had
responded to PCB or CCNU in vitro was258 PROCEEDINGS OF BACR 25TH AGM
significantly longer than both the RFI of patients
whose tumours failed to respond in vitro and the
RFI of those patients who had not been tested.
This difference was not attributable simply to an
imbalance in prognostic factors between the groups.
However, it was apparent that grade of tumour
influenced chemosensitivity in vitro. Patients with
grade III tumours responded well in vitro (16/22
patients sensitive to PCB or CCNU) whilst only
6/22 patients with grade IV tumours responded to
either of these drugs. It is hoped that this assay
may form the basis of a prospective randomised
trial ofchemosensitivity testing.
Improved in vitro determination of tumour
chemosensitivity in haematological malignancies
M.C. Bird, A.G. Bosanquet & E.D. Gilby
Department ofClinical Investigation, Royal United
Hospital, Combe Park, Bath BA] 3NG, UK.
We have further developed our 4-day
chemosensitivity assay previously described
(Bosanquet et al., 1983, Br. J. Cancer, 47, 781) so
that cell identification is greatly improved and
problems of cell autolysis and proliferation are
overcome. After continuous incubation of drug
with isolated white cells, dead cells are stained with
a mixture of fast green FCF and nigrosin and the
cultures cytocentrifuged. Remaining live cells are
counter-stained with Romanowsky stain. A known
number of fixed duck erythrocytes (DRBC) is
added to the stain as an internal standard. For
quantification of results the ratio of live tumour
cells to DRBC is determined for each slide and the
ratio in drug-tested samples expressed as a
percentage of that in control samples (TCV). Over
30 drugs have been tested in the assay, and all have
given a dose-response relationship and a good
scatter of sensitivities between patients.
Chemosensitivity of blood and bone marrow
samples was similar where both were tested
together. Twenty-three of 32 tests (72%)
undertaken with chronic lymphocytic, acute
lymphoblastic and acute myeloid leukaemias and
multiple myeloma have been technically successful.
Assay results could be correlated with in vivo
response in 12 cases. Three were sensitive both in
vitro and in vivo, 8 were resistant in vitro and in
vivo and one was sensitive in vitro but resistant in
vivo.
Patient intolerance to superficial hyperthermia
R.D. James & D. Pye
The Christie Hospital & Holt Radium Institute,
Manchester, UK.
The discomfort associated with superficial
hyperthermia is of two types. The first is due to
prolonged immobilisation. The second is due to
pain in the skin from high temperatures. Iso-
effective treatments using various times and
temperatures can be derived from animal work. We
have studied the tolerance of 25 patients to a
variety of hyperthermia schedules, thought to be
iso-effective for normal tissues. Of 30 treatments
using times in excess of 30min, 10 were discon-
tinued because of patient intolerance. Of 23
treatments using times of less than 10min only one
was discontinued. We believe the optimum schedule
for clinical treatment should not exceed 10min, and
should aim for a tumour temperature of at least
45°C. Skin pain can generally be controlled using
skin cooling or local anaesthetic.
Bone marrow repopulation following high dose
radiotherapy using indium-ill scanning
P.E. Cummins, R.D. James', S. McKenzie & P.M.
Nuttall
Regional Department ofMedical Physics and
'Department ofRadiotherapy, Christie Hospital
Manchester, UK.
Indium-111 bone marrow scanning has been used
to assess marrow damage and the extent of post
therapy recovery in patients with Hodgkin's disease
treated with mantle radiotherapy. The interval
between completion of treatment and time of
scanning varied from 3 months to 14 years. Bone
marrow scans were performed 3 days after i.v.
injection of 74MBq(2mCi) indium-111 choride
using a large field of view gamma camera. All scans
were recorded by computer on magnetic disc for
later retrieval and processing. The scans were
analysed quantitatively by measuring irradiated
bone to soft tissue ratios and irradiated to un-
irradiated bone uptake ratios. These ratios - all
determined with the region of interest (ROI)
technique - correlated significantly with time after
irradiation. Results indicate very slow repopulation
of irradiated marrow which returns to normal after
a period of 10 to 15 years. It is suggested that slow
repair of bone marrow stromal elements may be the
cause of this delayed repopulation.PROCEEDINGS OF BACR 25TH AGM 259
At mastectomy tumour size and axillary node status
predict time to relapse and steroid hormone receptors
predict survival after first relapse
R.N.L. Harland, A. Howell, D.M. Barnes, M.J.S.
Wilkinson & R. Swindell
Departments ofSurgery, Medical Oncology, Clinical
Research and Statistics, Christie Hospital,
Manchester, UK.
We found that neither oestrogen receptor (ER) nor
progesterone receptor (PR) status of the primary
tumour predicted time to relapse after mastectomy
but receptor positive tumours were associated with
a greater survival. This suggested that the survival
advantage was due to a greater survival after
relapse in patients with receptor positive tumours.
We have therefore examined the effect of other
prognostic factors (tumour size and axillary node
status) as well as receptors upon overall survival,
time to first recurrence after mastectomy and
survival after first relapse. ER was measured in 508
and PR in 496 primary tumours by the dextran
coated charcoal technique. With the exception of 32
treated with melphalan no additional treatment was
given after mastectomy. The median follow up was
36 months and the maximum was 91 months. One
hundred and thirty-seven patients relapsed and the
response to endocrine therapy was known in 65.
All variables indicated groups with different
probabilities of survival after mastectomy (size T
classification), P<0.005; nodal status, P<0.02; ER
status, P<0.0001; PR status, P<0.002. Both size
and node status identified groups with differing
probabilities of relapse (both P<0.0001), but
similar probabilities of survival after relapse.
Conversely neither ER nor PR status indicated the
probability of relapse although groups with
markedly different prospects of survival after
relapse were identified (ER and PR P<0.0001).
Thus greater survival after relapse was related to
the group of patients with receptor positive
tumours who responded to endocrine therapy. We
conclude that size and node status predict time to
relapse and receptor status predicts survival after
relapse in patients with cancer of the breast.
Nandrolone decanoate (N.D.) as an adjunct to
chemotherapy in the treatment of advanced
carcinoma of the breast
R.L. Turner, M.C. Bibby & D.M. Robertshawl
Clinical Oncology Unit, University ofBradford and
1Biochemistry Department, Bradford Royal
Infirmary, Bradford, UK.
In 1959, Whyte et al. (Br. med. J., i, 1315) observed
a synergistic effect when testosterone was
administered with thiotepa in advanced breast
cancer. They postulated that testosterone was
unlikely to cause androgenic inhibition of tumour
growth but rather to stimulate erythropoiesis and
bone marrow "protection". This hypothesis is now
tested with N.D., an anabolic steroid with 6
times the anabolic potency of testosterone but with
considerably fewer androgenic side effects. An open
controlled study was designed to investigate the
effect of N.D. as an adjunct to a standard cytotoxic
regime (Methotrexate and Thiotepa) on
haemopoiesis, host immunity and chemotherapeutic
response. Forty-five female advanced breast cancer
patients were randomised for either cytotoxic
therapy plus N.D. or cytotoxics alone. Full
haematological and biochemical assessments were
made at baseline and at weekly intervals up to day
63. Lymphocyte typing and immunoglobulin
measurements were performed at baseline, days 28
and 56. N.D. accelerated the recovery of red cell
haematological parameters following the depression
caused by cytotoxic therapy. Recovery was
complete in the N.D. group by the end of the study
period, 7 weeks after the cessation of the first
course of chemotherapy but not in the control
group. There was no evidence of renal or hepatic
damage by N.D. and only minor occurrences of
virilising side effects. The difference in remission
rates between N.D. and control groups was quite
striking. Three times as many N.D. patients
achieved complete remission when compared with
controls. It is not clear at present whether this is
due to an enhancement of cytotoxic action or to a
more direct anabolic effect either upon the host-
immune response or upon the metabolic status of
the patients or indeed a combination of both.
The effect of oestrogen and progesterone receptors on
recurrence and survival in patients with breast
cancers
J.M.T. Howat, D.M. Barnes, M. Harris & R.
Swindell
North Manchester General Hospital & Christie
Hospital & Holt Radium Institute, Manchester, UK.
Patients with breast cancer and oestrogen (REc)
and progesterone (RPc) receptors in their tumours
generally survive longer than those who lack them,
but whether the beneficial effect of receptors results
from a longer disease-free interval (DFI) or greater
survival after relapse is not clear.
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Recurrence and survival rates were studied in 175
women with primary breast cancer who, until
recurrence, received no treatment other than a
modified radical (Patey) mastectomy. The REc and
RPc content of the primary tumours was measured
by the dextran-coated charcoal method. At a
median follow-up of 47 months (range 55-58),
overall there was no difference in the DFI of
REc+ve and -ve patients although there was a
significant increase in the postmenopausal group
(P=0.02) and for those with 1-3 involved axillary
nodes (P=0.02). The status of RPc did not affect
the DFI in any patients.
Survival following mastectomy was significantly
better for REc+ve patients (P=0.006), especially
those who were postmenopausal (P=0.003) or node
+ve (P=0.01). Survival was also increased for
RPc+ve patients (P=0.04) and this too was
evident in postmenopausal patients (P=0.01).
There were significant differences in the post-
relapse survival (PRS) of REc and RPc+ve and
-ve patients (REcP=0.03, RPcP=0.001) and
patients with both REc and RPc survived
approximately 17 months longer than their
receptor-negative counterparts.
This study failed to confirm that measurement of
REc and RPc can predict early relapse in breast
cancer and the greater overall survival of receptor-
positive patients is mainly due to an increase in
PRS. This may reflect the response of receptor-
positive patients to endocrine therapy which the
majority received when they developed recurrent
disease.
A pilot study to evaluate the psychiatric morbidity in
patients with advanced breast cancer
P. Hopwood, A. Howell & G.P. Maguire
Department ofPsychiatry, University Hospital of
South Manchester, Withington and Department of
Medical Oncology, Christie Hospital, Manchester,
UK.
Although there has been extensive research into
psychosocial sequelae of treatments of early breast
cancer little attention has been paid to psychiatric
disorders in patients with advanced cancer of the
breast. The aim of this prospective study was to
determine the psychiatric morbidity in a group of
26 patients immediately before and during first line
chemotherapy. Patients underwent a standard
psychiatric interview by a Clinical Psychiatrist
before and after 2-3 months of treatment.
Depressive illness or anxiety states requiring further
intervention was found in 9 patients (35%),
occurring before chemotherapy in 5 (19%) and
during chemotherapy in 4 (15%). The psychological
disorder was equivalent to that found in patients
attending a psychiatric outpatient clinic. The illness
responded to anxiolytic or antidepressant
medication in 6 patients, in two the disorder
resolved as they responded to chemotherapy and
one patient died from metastatic disease. We
conclude that over one third of patients presenting
with advanced breast cancer may have psychiatric
morbidity and that this is amenable to treatment.
Our current approach is to screen all patients with
the aid of a questionnaire and to interview those
with high scores.
The treatment of bladder carcinoma with tumour-
immune pig lymph node cells - a phase I study
M.O. Symes, H. Eckert, R.C.L. Feneley, J.C.
Gingell, T. Lai, J.B.M. Roberts, P.J.B. Smith &
C.R. Tribe
Departments ofSurgery, Radiotherapy and
Pathology, University ofBristol and Bristol and
Weston and Southmead District Health Authorities,
UK.
A total of 77 patients with invasive TCC of the
urinary bladder, each received a single arterial
injection of tumour-immune pig lymph node cells
(LNC), into the tumour blood supply. The patients
were divided into 4 groups: (1) those receiving pig
LNC as the only treatment (16 patients); (2) those
who received pig LNC on relapse (judged by EUA
cystoscopy and biopsy) following radical
radiotherapy, 5500cGy (34 patients); (3) those who
received pig LNC followed after an interval of 6
weeks by radiotherapy (4000cGy) (10 patients); (4)
as in group (3) but with the dose of radiotherapy
increased to 5500cGy (17 patients). Complete
remission was characterised by complete
disappearance of the tumour (for a varying time)
following treatment. Partial remission was defined
as: a reduction in the level of symptoms and a
decrease in tumour size on EUA and/or cystoscopy.
There were 1 complete and 3 partial remissions
among the patients in group (1), 5 complete and 7
partial in group (2), 6 complete and 2 partial in
group (3) and 8 complete and 1 partial in group
(4). Of the 20 patients showing a complete
remission, 7 lived for more than 5 years after
treatment.PROCEEDINGS OF BACR 25TH AGM 261
Methodology for assay of thiotepa in plasma and
initial pharmacokinetic studies
B.J. McDermott, J.A. Double, M.C. Bibby, D.E.V.
Wilman1, P. Loadman & R.L. Turner
Clinical Oncology Unit, University ofBradford and
CRC Laboratories, Institute of Cancer Research,
Sutton, Surrey, UK.
ThioTEPA is being used currently in a controlled
randomized trial to assess the role of nandrolone
decanoate in combination regimes for advanced
ovarian and breast cancer. Clinical findings
(Turner, 1981, Excerpta Med. APCS, 9, 1) and
experiments with animal model systems (Double et
al., 1981, Br. J. Cancer, 44, 305) indicated that the
anabolic steroid increases the tolerance of bone
marrow to chemotherapy. In addition, a pharma-
cokinetic interaction may occur and for purposes
of this investigation, an assay for thioTEPA and
its metabolite, triethylenephosphoramide (TEPA),
was developed. After extraction from plasma using
SEP-PAK C18 cartridges, the compounds were
separated by capillary gas chromatography,
detected using a nitrogen detector and quantified
by reference to an internal standard,
hexaethylphosphoramide. Analytical recoveries were
73.6% and 95.2%, intra-assay variations (s.e.) were
5.6% and 7.5% (n = 12), and inter-assay variations
(s.e.) were 8.8% and 12.5% (n=6) for TEPA and
thioTEPA, respectively, at concentrations of
50ngml-1. The limit of sensitivity was 1-5 ngml-1
for both compounds. The elimination kinetics of
thioTEPA were biexponential in 3 of 6 patients and
the half-life of the initial phase was greater (range,
1.4-2.5h) than in mice (mean+s.e., 14.0+0.4min).
The extent of binding of therapeutic concentrations
of TEPA and thioTEPA to human plasma
components under physiological conditions was
determined by ultrafiltration and was <40%. It is
unlikely, therefore, that competition for protein
binding sites by concomitantly administered steroid
will have any significant effect on plasma levels of
the pharmacologically-active agents.
Initial results with ovarian cancer antigen CA125
P.A. Canney', M. Moore2, R.D. James3 & P.M.
Wilkinson
'Department ofClinical Pharmacology, 2Paterson
Laboratories, 3Department ofRadiotherapy, Christie
Hospital and Holt Radium Institute, Manchester, UK.
CA125 has been measured in serum of patients
using the method previously described by Bast
et al., 1983, N.E.J.M., 309, 883). Nineteen of 23
(83%) patients with epithelial ovarian carcinomas
exhibited elevated CA125 levels (>35Uml-1).
Although considerable interpatient variation
occurred, there was a positive association between
the elevation of CA125 and estimated body burden
of tumour. One patient thought to have had
complete resection of early stage ovarian cancer
had an elevated CA125 level at 16 days post-
operatively; 3 further patients who had complete
resections had a normal level when assayed at 22,
33 and 90 days post-operatively. Sequential
measurements at an interval of one month were
performed on 8 patients who had received
chemotherapy. The half life of CA125 varied
between 5 and 95 days; in 5 patients being between
5 and 10 days. An acute rise in response to
chemotherapy, occuring within the first 5 days after
treatment, was seen in 3/4 patients studied. Four
out of five patients with uterine endometrial
carcinoma and 2/2 patients with adenocarcinoma of
the cervix had raised CA125 levels, 3/4 patients
with large bowel carcinoma had raised CA125
levels. None of 19 in a control group consisting of
patients in complete remission following
chemotherapy for lymphoma, showed elevated
CA125 levels (mean 10.9+4.4Uml-1). The lack of
specificity with regard to major differential
diagnoses for ovarian cancer renders the antigen
unsuitable as a diagnostic or screening tool.
However, the high true positive rate and this
demonstration of short term variations in CA125
levels in response to chemotherapy indicate
considerable promise for its use on a marker to
monitor treatment. It may also be of value in the
management of uterine carcinoma.
A study of secretory component in breast cancer
using monoclonal and polyclonal antisera
M.E. Gore, B.A. Gusterson, R.C. Coombes &
R.A.J. McIlhinney
Ludwig Institutefor Cancer Research, Royal
Marsden Hospital, Sutton, Surrey, UK.
The mouse monoclonal antibody LICR-
LON-LC28 binds to both secretory IgA and free
secretory component having a 10-fold greater
affinity for the former. This differential affinity can
be exploited, using immunohistochemical methods,
to study the distribution of secretory IgA in tissue
sections. The antibody is species specific and does
not bind to rat, sheep or bovine secretory IgA.
Immunohistochemical studies of tissue sections
stained with LICR-LON-LC28, conventional
antisera to human secretory component and human262 PROCEEDINGS OF BACR 25TH AGM
alpha chains, confirmed that LICR-LON-LC28 can
be used to study the distribution of secretory IgA,
except where free secretory component is present in
very large quantities.
Five out of 22 breast carcinomas showed
evidence of secretory component production. IgA
was absent from these five tumours and was present
only in the cytoplasm of plasma cells infiltrating the
tumours. This suggests that secretory component is
not usually produced by breast cancers but that
when it is present it is unable to blind IgA.
Oestrogen receptors and prognosis in disseminated
breast cancer
R.A. McClelland1, T.J. Powles', & R.C. Coombes2
'Royal Marsden Hospital and 2Ludwig Institutefor
Cancer Research, Sutton, Surrey, SM2 5PX, UK.
The importance of oestrogen receptor (ER)
presence in the prognosis of disseminated breast
cancer was investigated by actuarial analysis of
follow up data from 305 patients with advanced
disease. All patients had ER content assessed on
primary tumour material by the dextran-coated
charcoal method (McGuire et al., 1975, In:
Estrogen Receptors in Human Breast Cancer. p.1).
Of the 305 patients, 278 were assessable for
response to therapy by UICC criteria. Seventy five
showed complete or partial tumour regression, 71
had their disease stabilised and 132 had progressive
disease despite treatment.
ER positive patients (111) did significantly better
(P=0.025) than ER negative patients (79) with
respect to their length of survival from first relapse
to death (ER +ve>15 femtomoles receptormg-
cytosol protein).
The length of survival from primary diagnosis
and the disease free interval from primary diagnosis
to first relapse were found to be unrelated to
receptor content of the primary tumour although
there was a trend towards longer overall survival
from presentation in the ER +ve group.
These findings echo similar results from work
with early breast cancer (Stages I and II) (Stewart
et al., 1983, Eur. J. Cancer Clin. Oncol., 19, 1381)
and suggest that the presence of ER significantly
affects patients but not their disease free interval.
Uptake and incorporation of CCRG 81010 (M & B
39565, NSC 353451) into TLX5 mouse lymphoma
A.C. Horgan & M.J. Tisdale
CRC Experimental Chemotherapy Group,
Department ofPharmacy, University ofAston,
Birmingham, B4 7ET, UK.
CCRG 81010 (8-carbamoyl-3-(2-chloroethyl)
imidazo [5,1-d]-1,2,3,5-tetrazin-4-(3H)-one) is a new
antitumour drug with a broad spectrum of activity
against murine tumours and is at present entered
into a Phase I clinical trial. Preliminary
investigations into its mode of action indicate that
activity may be exerted via 5-[3-(2-chloroethyl)
triazen-1-yl] imidazole-4-carboxamide (MCTIC), a
possible metabolite of CCRG 81010. (Horgan et
al., 1983, Br. J. Cancer, 48, 132).
In this study, we hoped to define the uptake of
drug into tumour cells and the intra-cellular fate of
the label. Uptake experiments were performed with
TLX5 lymphoma using [6-14C-imidazole] CCRG
81010. The rate of uptake was rapid and
temperature dependent (equilibrium within 1 min at
37°C and 6min at 4°C), directly proportional to
drug concentration and independent of metabolic
inhibitors. A cell:medium distribution ratio of
unity was achieved suggesting a passive diffusion
process. No difference in uptake was seen between
drug sensitive and resistant cells.
Radioactivity was found to be progressively
accumulated into acid-insoluble material. Acid
hydrolysis followed by HPLC separation of
DNA/RNA components showed that the
radioactivity was associated solely with adenine and
guanine. Over a 24h period about 80% of the
CCRG 81010 in the medium was converted to 5-
aminoimidazole-4-carboxamide (AIC). Non-radio-
labelled AIC suppressed the incorporation of
radioactivity into nucleic acids but had no effect on
the initial rate of uptake of CCRG 81010. It was
concluded that all the radioactivity in DNA and
RNA was due to the salvage of AIC for de novo
base synthesis.
Anti-tumour activity of CCRG 81010 on a panel of
transplantable tumours in MRI mice
J.A. Double & M.C. Bibby
Clinical Oncology Unit, University ofBradford,
Bradford BD7 JDP, UK.
CCRG 81010 is a new anti-cancer drug with a
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(Stevens et al., Br. J. Cancer, 48, 120). In this study
this agent has been tested against four
transplantable mouse adenocarcinomata of the
colon lines (MAC 13, 16, 26 and 15A) of varying
growth characteristics and histology and a newly
developed mouse lymphoma BML1. These tumour
lines are generally non-responsive with useful effects
only seen close to maximum tolerated dose. Best
responses are seen with the nitrosoureas and
cyclophosphamide. MAC 15A and BML1 are
assessed by survival duration, MAC 13 by
comparison of the ratio of treated tumour weights
over control tumour weights and MAC 16 and
MAC 26 assessment of growth delays at relative
tumour volume 5.
A 73% extension in median survival time was
produced in MAC 15A and an 80% extension in
BLM1. Ninety-nine percent tumour inhibition was
seen in the solid line MAC 13 and a 6 day growth
delay was seen in MAC 26. Mac 16 was
unresponsive. The anti-tumour responses seen with
CCRG 81010 in these tumours are very similar to
those seen with MeCCNU, currently the most
active agent in the MAC series. Of the 2 slower
growing tumours MAC 16 is unresponsive and
MAC 26 only poorly responsive to both agents at
maximum tolerated dose. Reasons for these
variations in response are currently under
investigation.
In view of its exciting preclinical activity similar
to that previously shown by the nitrosoureas, it is
to be hoped that the same disappointing clinical
outcome does not follow.
Mechanism of resistance to methotrexate (MTX) in
human tumour xenografts
S.J. Harland, A.H. Calvert, M. Jones, Z. Siddik &
K.R. Harrap
Institute ofCancer Research, Sutton, Surrey, UK.
Six human tumour xenografts grown in nude mice
were tested in vivo against MTX. Only one of them,
an acute myeloid leukaemia grown as a solid
tumour, was sensitive. Groups of xenograft-bearing
mice were then given MTX 100mgkg-1 i.p. and
the dihydrofolate reductase (DHFR) activity of the
cytosol of the tumours was determined at intervals.
This apparent enzyme activity rose between 1.7 and
12.0-fold in the resistant tumours, usually peaking
at 3-4 days after treatment, but fell in the sensitive
tumour to 0.3 of the pretreatment value. These
findings concur with studies on patients with acute
leukaemia (Bertino, et al., 1977, Cancer Treat. Rep.
61, 667). However, measurement of the total MTX
level in the supernatants and determination of Ki's
for the inhibition of DHFR by MTX allowed the
total DHFR content to be calculated. This rose
1.4-1.8-fold in the sensitive tumour, a value in the
same range as those for the resistant tumours which
contained very little MTX. Studies of the kinetics
of the affinity purified DHFR from a resistant
melanoma line suggested the existence of 2-types of
DHFR with Ki's for MYX of 2.2 and 295pM. The
Ki of DHFR from the sensitive leukaemia line was
1.1 pM with no evidence of a low affinity form.
These studies suggest that intrinsic resistance of
human tumours may be mediated by the presence
of a form of DHFR which is poorly inhibited by
MTX. Short term changes in total DHFR levels did
not differentiate the sensitive tumour from the
resistant ones. Transport of 3HMTX into tumour
slices was increased by low temperatures and
metabolic inhibitors - the reverse situation from
that described for murine systems.
Methotrexate may be neurotoxic by interference with
tetrahydrobiopterin metabolism
J.A. Blair, C. Morar & S.B. Whitburn
Chemistry Department, University ofAston,
Birmingham B4 7ET, UK.
Tetrahydrobiopterin (THB) is the coenzyme
required for the formation within the CNS of the
neurotransmitters dopamine, noradrenaline and
serotonin. Methotrexate (MTX) inhibits
dihydropteridine reductase (DHPR)
(K-=6x 10-5M), the enzyme which maintains
THB in its fully reduced form. Thus the
neurotoxicity of MTX may be due to interference
with THB metabolism in the CNS.
The levels of THB and its oxidation products
7,8-dihydrobiopterin (DHB) and biopterin (B) were
measured in whole rat brain using HPLC, acid-
iodine oxidation and alkaline-iodine oxidation. In
adult male control rats (10) total biopterins were
222.4+45.8 (mean+s.d.)pmolg-1 wet weight, of
which 95.3% was THB, 2.8% was DHB and 1.9%
was B. Four hours after an oral dose of MTX
(1 mgkg-1) (6 rats) total brain biopterins were
increased to 351.9+134pmolg-1 wet weight
(P<0.01) and the percentage distribution of THB,
DHB and B was unchanged. With an oral dose of
100mgkg-1 (6 rats), after total brain biopterins
were similar to controls (188.6 +34.3pmolg- wet
weight) but the distribution of the biopterins was
significantly altered. Percent THB was 76.7
(P<0.01 compared to control), DHB was 18.7
(P<0.025) and %B was 4.6 (P<0.01).264 PROCEEDINGS OF BACR 25TH AGM
Large doses of MTX therefore affect THB
metabolism and significantly lower the levels of the
active coenzyme while increasing the amounts of its
inactive oxidised derivatives.
combination of Cisplatin and Methotrexate in these
xenografts is at least additive and may be showing
some synergism.
This work was supported by the Cancer Research
Campign.
The effect of combined cisplatin and methotrexate on
two human bladder cancer xenografts
J.H. Hay & W. Duncan
University Department of Clinical Oncology,
Western General Hospital, Edinburgh, UK.
Cisplatin (CDDP) and Methotrexate (MTX) are
two of the most active agents available to treat
metastatic transitional cell carcinoma (TCC). A
combination of the two could have useful clinical
applications if their effects were additive or,
preferably, synergistic. We have used two
xenografts - WX38 a grade 3] [TCC and WX48 a
grade 2] [TCC - growing in immune-deprived mice
(Hay et al., 1982, Br. J. Cancer 46, 465) to study
the effect of this combination. Specific Growth
Delay (SGD) has been used to assess the response
of the xenografts to treatment and the effect of
combinations of the drugs has been assessed using
isobolograms from which the effect of an additive
combination may be predicted. A synergistic
combination will show effects greater than
predicted and vice versa. The results are shown in
the table below:
Cisplatin
Dose in mgkg 7 4 2
WX38 SGD values 1.5 0.9 0.1
WX48 SGD values 0.6 0.4 0.1
Methotrexate
Dose in mgkg 70 40 20
WX38 SGD values 2.0 1.4 0.5
WX48 SGD values 0.5 0.4 0.3
WX38 3mgkg-1 CDDP and 30mgkg -1 MTX
SGD= 2.9 (predicted 1.5-2.0)
WX48 1 mgkg 1 CDDP and 40mgkg-1 MTX
SGD=0.7 (predicted 0.5)
WX48 2.5mgkg-CDDP and 25mgkg -1 MTX
SGD =0.7 (predicted 0.5)
Studies on the mechanism of CB3717 induced
hepatotoxicity
D.R. Newell, D.L. Alison, A.L. Jackman, A.H.
Calvert & K.R. Harrap
Department ofBiochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey, UK.
CB3717 (N-(4-(N-((2-amino-4-hydroxy-6-quinazo-
linyl)methyl)prop-2-ynylamino)benzoyl)-L-glutamic
acid) is an antifolate inhibitor of thymidylate
synthetase currently undergoing clinical evaluation
at a number of centres in the UK. Hepatotoxicity is
the most prevalent side-effect observed with
CB3717; 50% of patients develop elevations of
plasma alanine transaminase (ALT) to over twice
the upper limit of normal. In mice CB3717 also
produced elevations of plasma ALT which were
maximal 6h after a single i.p. dose, returning to
normal by 24h. After 100mgkg-1 CB3717, plasma
ALT levels of 2-30 xcontrol were observed whilst
at 300mgkg-1 ALT elevations of 28-50 fold were
produced. The administration of thymidine
(2 x 500mgkg-1), 5-methyltetrahydrofolate (1 or
3 x lOmgkg-1) or folinic acid (1 or 3 x lOmgkg-1)
did not reduce CB3717 hepatotoxicity in mice. As
thymidine and folinic acid can abolish the
antitumour activity of CB3717 it is unlikely that
hepatotoxicity is mediated through inhibition of
liver thymidylate synthesis. Although CB3717
can produce a 40% depletion of liver total non-
protein thiols the administration of N-acetyl
cysteine (500mgkg-1) did not reduce CB3717
hepatotoxicity. Studies with structurally related
quinazolines showed that equimolar doses of the
N10-ethyl and N10-unsubstituted analogues
produced no hepatotoxicity. However, pharma-
cokinetic studies demonstrated that plasma
quinazoline levels following the two analogues were
considerably lower (<I/Oth) than those observed
after CB3717. This suggests that the liver damage
produced by CB3717 may limit its hepatic
clearance. Furthermore, CB3717 hepatoxicity is
apparently related to the N10-prop-2-ynyl
substituent.
Although the SGD values produced by the
combinations are all greater than predicted for a
purely additive effect, these differences do not reach
statistical significance. It is concluded that thePROCEEDINGS OF BACR 25TH AGM 265
A new quinazoline antifolate drug CB3717 which
inhibits the growth of human liver cancer cells in
athymic mice, cell culture and patients
N. Curtin, A.L. Harris', O.F.W. James & M.F.
Bassendine
Departments ofMedicine and Clinical Oncology1,
University ofNewcastle upon Tyne, UK.
The prognosis of patients with primary liver cancer
(PLC) is poor, despite the currently available
chemotherapy. Since thymidylate synthetase activity
is high in PLC cells, we have studied a new
quinazoline antifolate drug, CB3717, which inhibits
this target enzyme (Jones et al., 1981, Eur. J.
Cancer, 17, 11). The effect of CB3717 on the
growth of human PLC cells, PLC/PRF/5, was
studied in tissue culture and as a solid tumour in
athymic mice.
Tumour growth was measured by serial serum
AFP levels, a reflection of viable tumour mass
(Bassendine et al., 1983, Clin. Sci., 64, 643), and by
direct volume estimation. Measurements from mice
bearing visible tumours treated for 5 days with
either 125mg or 200mg CB3717Kg -1day -1 i.p. or
two 5-day courses of200mg CB3717Kg 1 day - I i.p.
separated by 9 days were compared with those
obtained from control tumour-bearing mice.
Serum AFP concentrations were significantly
reduced compared to controls in low dose (P<0.05)
and high dose (P<0.02) groups, tumour volume
was significantly reduced in the high dose (P<0.05)
group only. A second period of drug administration
further reduced tumour growth, as measured by
AFP levels. In vitro experiments give an ID50 of 1-
5 uM, which is in the range achieved by the dose of
300mgm-2 given to patients. Our study shows that
CB3717 is a potent inhibitor of human PLC growth
in vivo and in vitro. Unlike methotrexate it
preserves de novo purine synthesis, leading to low
toxicity and its therapeutic efficiency is reflected in
an early clinical evaluation.
Studies on the pharmacokinetics and metabolism of
some dimethylphenyltriazenes
C.J. Rutty, R.B. Vincent, G. Abel, P.M. Goddard
& K.R. Harrap
Department ofBiochemical Pharmacology, Institute of
Cancer Research, Belmont, Sutton, Surrey, UK.
A number of dimethylphenyltriazenes have been
synthesised in a search for a suitable clinical
alternative to DTIC, which have demonstrated
activity in experimental tumour systems. It is
believed that, like DTIC, such compounds require
metabolic activation, i.e. oxidative N-demethylation
resulting in the formation of an unstable
monomethyltriazene metabolite which on
decomposition yields a species capable of
methylating cellular macromolecules. I-p-
Carboxyamidophenyl-3,3-dimethyltriazene (CB 10-
286) showed marked activity versus a mouse PC6
plasmacytoma (T.I. =56), and is very rapidly
metabolised in the mouse (plasma
t-f3 =3.7+0.25min). This resulted in high plasma
levels (103.5 +3.2MM) of I-p-carboxyamidophenyl-
3-monomethyltriazene (CB 10-347), the putative
active metabolite (AUC= 1159.2,uM xmin). These
levels are comparable to those produced by direct
administration of CB 10-347 to mice
(AUC = 1184.2pM xmin) which gave similar
inhibition of tumour growth. In the rat plasma
clearance of CB 10-286 was slower
(tBfl= 16.9+0.86min), and the peak levels of CB
10-347 were much lower (26.4+4.2,M), although
still some 13 times greater than the levels of the
corresponding monomethyl metabolite produced by
DTIC metabolism in the rat. Despite significant
activity of 1-p-carboxyphenyl-3,3-dimethyltriazene
(CB 10-277) against the PC6 tumour (T.I. =21.5)
this compound failed to undergo N-demethylation
in vitro in contrast to the carboxyamido derivative.
The plasma t-fl for this compound in mice
(93.1 +8.9min) is also considerably longer than for
CB 10-286, and there is no apparent formation of a
monomethyl metabolite in vivo. Thus the
antitumour activity of this drug does not appear to
be dependent on oxidative metabolism.
Derivatives of hydroxymethyltriazenes: Potential
prodrugs of the active metabolite of
aryldimethyltriazenes
K. Vaughan, R.J. LaFrance, C.M. Hemens, Y.
Tang & D.C. Chubb1
Department ofChemistry, Saint Mary's University,
Halifax, N.S., Canada, and 1CRC Experimental
Chemotherapy Group, Department ofPharmacY,
University ofAston, UK.
Recent metabolic studies (Rutty et al., 1983, Brit. J.
Cancer, 48, 140) suggest that the poor clinical
activity of DTIC is due in part to the low level of
oxidative metabolism of the drug in man. New a-
substituted triazenes are being investigated for anti-
tumour properties as potential prodrugs for the266 PROCEEDINGS OF BACR 25TH AGM
oxidative metabolites of DTIC and other
dimethyltriazenes.Hydroxymethyltriazenes,ArN =N-
NRCH2OH, are synthesised by coupling an
aryldiazonium ion to the carbinolamine,
RNHCH2OH, generated in situ from formaldehyde
and the alkylamine. Hydroxymethyltriazenes react
with acetic anhydride in pyridine to afford the
acetoxymethyltriazenes, ArN=N-NRCH2OAc, and
with benzoyl chloride in pyridine to yield the
benzoates, ArN=N-NR.CH2OCOPh. These
derivatives are suitable prodrugs since they should
not require metabolic oxidation to exert a cytotoxic
effect. The acetates and benzoates react with
methanol to give the methoxymethyltriazenes,
ArN=N-NRCH2OMe, which may be suitable
prodrugs through 0-demethylation. The antitumour
activity of a hydroxymethyl-, acetoxymethyl-, and
methoxymethyltriazene has been compared with the
activity of the corresponding dimethyl- and mono-
methyltriazenes (see Table).
Optimum




ArN =N-NMe.CH2OAc 40 56
ArN =N-NMe.CH2OMe 40 68
ArN =N-NMe.Ch2O-COPh 20 31
(Ar =p-MeO2C.C6H4-)
1. 2 x 105 TLX5 lymphoma cells S.C. day 0 into CBA
mice in groups of 5. Drugs administered days 3 to 7.
2. A. Gescher, 1981 et al., Biochem. Pharmacol., 30, 89.
analysis of the amine, employing low wavelength
UV detection and have subsequently investigated its
production and distribution in mice, 3 h after a
single i.p. dose of 650mgkg-' benznidazole. This
dose produces plasma benznidazole concentrations
of 120-130jugml-1 with tumour/plasma ratios of
80-100% in C3H mice bearing RIF-I and KHT
tumours, and BALB/c mice bearing EMT6
tumours. Plasma amine concentrations were very
low (0.3-0.7ygml-1) with similarly low amounts
present in the 2 C3H mouse tumours (0.3-
1.4,jgg-1). Higher concentrations were detected in
EMT6 tumours (4.lgug-1+0.33 SE, n=16)
suggesting that this tumour may be more hypoxic
or have greater nitroreductase activity than RIF-1
and KHT tumours. Livers from these C3H mice
contained very high levels of amine (51 jigg 1 +2.5,
n= I1) implicating this tissue as a major site of
nitroreduction. Both strains of mice excreted - 3%
of administered benznidazole as the amine in the
24h urine, with a further 4% as the parent
compound. We have also demonstrated in vitro
nitroreduction of benznidazole using whole liver
homogenates. The reaction is inhibited by oxygen
and has an absolute requirement for reduced
nicotinamide adenine dinucleotides, particularly
NADPH. In summary, nitroreduction of
benznidazole has been shown to occur in mouse
tissue in vivo and in vitro, and its clinical
significance is under investigation.
Misonidazole enhancement of the action of melphalan
in a human breast tumour xenograft
A.M.L. Coombs & J.L. Moore
Nitroreduction of the chemosensitizer and
radio-sensitizer benznidazole in vivo and in vitro
M.I. Walton & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
Benznidazole is a lipophilic analogue of misonida-
zole currently undergoing phase I clinical trial as a
chemosensitizer, in combination with the
nitrosourea CCNU. Reductive metabolism of
nitroimidazoles to their amine derivatives has been
implicated in the mechanism of cytotoxicity and
chemosensitization, possibly through the production
of chemically reactive intermediates. To study
benznidazole nitroreduction we have developed a
reverse-phase paired -ion HPLC technique for the
Department ofRadiobiology, Velindre Hospital,
Cardiff, UK.
A human breast tumour xenograft, HX99 (donated
by A.C. Jones, Royal Marsden Hospital, London),
implanted in immune suppressed female CBA mice
(Steel, 1978 et al., Br. J. Cancer, 37, 224), has been
used to study the in vivo chemosensitization of
melphalan (MEL) by misonidazole (MISO). Mice
bearing tumours of approximately 8mm diameter
were injected i.p. with drugs delivered in
0.01 ml- g. MEL was used in doses of up to and
including the LD10 value (14mg-1kg). MISO was
administered as total doses of 1 mg- g, 0.5mg-1 g,
0.25mg-1 g, and 0.1 mg-1 g. Tumours were excised
after 20h and cell kill determined by a soft agar
assay (Courtenay & Mills, 1978, Br. J. Cancer, 37,
261). MEL at 14mg -kg gave a 40% cell kill and
MISO alone at I mg- I g gave no significant cell
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was seen, for example, with total doses of 1 mg'-I g
and 0.5mg-1g, a cell kill of greater than 96% was
produced.
Effect of preheat on intracellular adriamycin
concentration and resulting surviving fraction of
EMT6 cells in vitro
S.H. Chambers, N.M. Bleehen, & K. Wright
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
Inhibition of liver microsomal metabolism of CCNU
by nitroimidazoles - correlation with
chemosensitisation activity
F.Y.F. Lee & P. Workman
MRC Clinical Oncology and Radiotherapeutics
Units, Cambridge, UK.
We previously showed that misonidazole (MISO)
reduced the clearance of CCNU in mice resulting in
a selective increase in tumour CCNU
concentration, and we proposed this to be the
major mechanism of chemosensitisation and
therapeutic gain (Lee & Workman, 1983, Br. J.
Cancer, 47, 659). Since both MISO and CCNU
undergo extensive metabolism in the liver, the
reduced clearance of CCNU is likely to be due to
the effect of MISO on hepatic CCNU metabolism.
We have therefore studied the effect of a range of
nitroimidazoles of varying chemosensitisation
activity (Workman & Twentyman, 1982, Br. J.
Cancer, 46, 249) on the metabolism of CCNU by
mouse liver microsomes. Microsomes were
prepared by standard subcellular fractionation.
CCNU and its metabolites were separated and
individually quantitated using a reversed-phase
HPLC method. In the presence of 02. glucose-6-
phosphate, glucose-6-phosphate dehydrogenase and
NADP, CCNU is metabolised to at least 5 different
ring-monohydroxylated active derivatives. Values of
Km and Vmax for the formation of the major
metabolite cis-4-hydroxy-CCNU were 0.028 mM
and 2.08 nmoles min-1mg-1 microsomal protein
respectively. MISO inhibits the rate of formation of
the metabolites with an ID50 of 6.4mM. Values of
ID50 for the various nitroimidazoles were in the
order: benznidazole <RoO7-1902 <MISO<RoO5-
9963< SR-2508. At concentrations similar to the
achieved plasma concentrations in mice given 2.5
mmoleskg-1, the extent of inhibition of CCNU
metabolism was 80% for benznidazole, 65% for
RoO7-1902, 33% for MISO, and 0% for RoO5-9963
and SR-2508. Therefore these data show that the
order of effectiveness of nitroimidazoles in
inhibiting microsomal CCNU metabolism directly
correlates with the order of efficacy for enhance-
ment of tumour response and provide further
evidence for the pharmacokinetic mechanism of
chemosensitisation.
We have investigated the response of exponentially
growing EMT6 tumour cells, in vitro, to treatment
with hyperthermia (1 h at 43°C) prior to treatment
with Adriamycin (ADM) (0-20pgml-1 for 1 h at
37°C). Relative intracellular ADM concentration
was measured by flow cytometry (FCM) and
compared with survival data (clonogenic assay).
FCM demonstrated that control cells accumulated
twice as much ADM as preheated cells. However,
FCM measurements of ADM in cells permeabolised
after heat treatment but before drug administration
indicated that hyperthermia did not significantly
alter the amount of ADM that could be
accumulated once the membrane barrier had been
removed. Survival data showed that preheated cells
had a higher surviving fraction than control cells,
0.3 at 3 igml-l compared to 0.007 for unheated
cells, as predicted by FCM. However, comparing
surviving fraction data with intracellular drug
measurement revealed that preheated cells were less
sensitive to a given internal ADM concentration (at
an FCM measurement of 100 fluorescence units
preheated cells have a surviving fraction of 0.1
compared to 0.01 for non-heated cells.) This
suggests that the initial observed difference in
surviving fraction is not due simply to a difference
in accumulation of ADM but also a change in the
intrinsic sensitivity of cells that have been subject to
preheating at 43°C. We conclude therefore, in
EMT6 cells, preheating for 1 h at 43°C protects the
cell from ADM by reducing the amount of drug
entering the cell, apparently by altering membrane
permeability, and also protects the cell by reducing
its sensitivity to the drug that does pass through the
membrane.
The response of V79 and human tumour multicellular
spheroids to adriamycin and in MAMSA: Cell survival,
growth delay and ultrastructural studies
J.M. Walling', S.K. Townsend', C.M.L. West2 &
I.J. Stratford'
1MRC Radiobiology Unit, Harwell, Didcot, Oxon,
U.K., 2University ofRochester Cancer Center, 601
Elmwood Avenue, Rochester, USA.
Three-dimensional spheroids can be regarded as
good in vitro models for solid tumours. It has been268 PROCEEDINGS OF BACR 25TH AGM
suggested that cell to cell contact can be an
important mediator of the response of spheroids to
damage caused by radiation and cytotoxic drugs.
We have been assessing the role of contact effects
in the radiation and drug response of V79 and
human tumour spheroids (ME/MAR small cell
lung carcinoma cell line and HX 117 - melanoma
xenograft). This report describes a comparative
study of the ultrastructural and cytotoxic effects of
the intercalating agents, adriamycin and mAMSA.
Electron microscopic examination shows that V79
spheroids are characterized by the possession of
desmosome type junctions as well as tight junctions,
HX 117 have many fewer desmosome typejunctions,
and ME/MAR spheroids lack any recognizable
junctions whatsoever. Both adriamycin and
mAMSA cause degeneration of cell membranes
within spheroids at doses that do not cause any
recognizable nuclear aberrations. The membrane
effects are most marked near the outside of the
spheroid and are not apparent towards the centre,
the region containing the quiescent cells and
hypoxic cells.
Relationship between bone marrow glutathione and
glutathione S-transferase. levels and drug priming
D.J. Adams, J. Carmichael, J.F. Smyth & C.R.
Wolf.
Imperial Cancer Research Fund, Medical Oncology
Unit, Western General Hospital, Edinburgh, UK.
Drug priming is a phenomenon where a small
"priming" dose of a cytotoxic compound will
protect patients from the acute toxicity of a much
higher dose of the same or a different compound.
In the present study we have investigated the
relationship between priming as protection against
cyclophosphamide (CP)-induced-myelotoxicity, and
reduced glutathione (GSH) and glutathione-S-
transferase (G-S-T) levels in the mouse bone
marrow.
CBA mice survived an otherwise lethal dose of
CP (350mgkg-1) when "primed" with an injection
of 75mgkg-1 CP five days prior to the lethal dose.
Our data demonstrate that a lethal dose of CP
caused a dramatic depletion of GSH in the bone
marrow and that the extent of this depletion was
limited by a priming dose of CP. Although a
priming dose of CP caused an initial depletion of
GSH, the GSH content of the marrow in primed
animals was 180-290% that of controls at day 5.
The time course of intracellular glutathione levels
mirrored the susceptibility of the mice to a lethal
dose of cyclophosphamide. This was also the case
for glutathione S-transferases which on day 5 were
dramatically increased over control values (252%
control).
We postulate that survival of primed animals
injected with an otherwise lethal dose of CP five
days after priming is due, at least in part to the
high levels of GSH and G-S-T detected in the bone
marrow. That is, that the "overshoot" of GSH and
G-S-T allows for the removal of the fatally
myelotoxic products of cyclophosphamide metabol-
ism through conjugation with GSH.
Molecular events in the formation of the tumour
marker, gamma glutamyl transpeptidase
C.A. Power*, J.L. Simpson & M.M. Manson
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey, UK.
Gamma glutamyl transpeptidase (GGT), a mem-
brane bound glycoprotein consisting of 2
heterologous subunits, exists as several isosymes,
varying in their degree of glycosylation. Enzyme
levels are high in fetal rat liver, while the very low
activity in adult liver is confined mainly to bile duct
epithelia. However, exposure to a wide range of
carcinogens leads to the formation of preneoplastic
foci of hepatocytes, many of which are GGT
positive.
To investigate the role of GGT in carcinogenesis
we are studying the molecular events in the
formation of the enzyme. Total RNA has been
isolated by guanidinium isothiocyanate extraction
from rat tissues rich in GGT, i.e. kidney, aflatoxin
B1 (AFB1) fed-liver and a tumour cell line derived
from such a liver. In vitro translation of RNA using
the rabbit reticulocyte lysate system and
immunoprecipitation of specific translation
products using anti-kidney GGT polyclonal
antibody** and protein A have been used to
identify the non-glycosylated pre-protein form of
the enzyme. RNA preparations have been enriched
for the mRNA of interest by fractionation on 5-
20% sucrose gradients and by oligo-dT-cellulose
chromatography.
Such enriched mRNA preparations have been
used to synthesize cDNA, which in turn can be
used as a probe to investigate the effect of
carcinogens on mRNA populations and
transcription of the gene(s) for GGT.
*Funded by National Foundation for Cancer Research.
**Kindly provided by Dr. S. Murphy, Open University.PROCEEDINGS OF BACR 25TH AGM 269
Monoclonal antibody to show heterogeneity in
normal and carcinogen fed rat liver
M.M. Manson & J.A. Green
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey, UK.
Monoclonal antibodies have been raised against a
y-glutamyl transpeptidase (GGT) positive rat liver
tumour cell line (JBl) from an aflatoxin (AFB1) fed
F344 rat. BALB/c mice were immunized with JB1
cells and spleen cells fused with NSO myeloma
cells. Hybridoma supernatants were screened
against JB1 cells by ELISA, and positive cultures
further screened by immunohistochemistry on cold
acetone-fixed sections of control and AFB1-fed rat
liver using anti-mouse y chain alkaline phosphatase
immunoconjugate. Twenty six cultures were selected
and one cloned twice in soft agar. This hybridoma
MRC TU/Jl secretes IgGl immunoglobulin which
has been used to follow changes in antigen
distribution in response to AFB1 administration.
In control neonatal and young male rat liver the
membrane bound antigen is evenly distributed
throughout hepatocytes. Older control animals
(> 12 weeks) show a zonal distribution with
stronger stain in periportal regions. Bile ducts are
stained in all sections. The zonal staining becomes
stronger during the first weeks of AFB1 feeding
(4ppm) when GGT-+ve biliary hyperplasia occurs.
From 4wks, when GGT- +ve foci appear, the
antigen distribution becomes increasingly hetero-
geneous with some foci heavily stained, other
apparently negative. Areas of biliary hyperplasia
are darkly stained. In serial sections stained for
GGT, foci positive for this enzyme are often
negative or heterogeneous with respect to antigen
distribution. This monoclonal antibody demon-
strates, more clearly than GGT histochemistry, the
heterogeneity among hepatocytes in control and
particularly carcinogen treated liver.
Changes in growth factor receptor function during
chemical hepatocarcinogenesis
B.I. Carr1, A. Lev-Ran, Z. Yosefsberg, G.
Barseghian & D. Hwang
1Departments ofMedical Oncology and
Endocrinology and Diabetes, City ofHope Natl.
Medical Center, Duarte, California, 91010, USA.
Insulin and epidermal growth factor (EGF) are
known hepatic mitogens. We have measured the
binding of insulin and EGF to liver during
chemical carcinogenesis to identify growth
regulatory changes that may be of importance.
Young adult male F344 rats were fed either a basal
diet or one supplemented with 2-
acetylaminofluorene 0.02%(AAF). After sacrifice,
livers were perfused, excised and microsomal and
Golgi membranes were prepared. Binding was
performed using 1251-insulin or -EGF in vitro at
+4°C. A decrease in the binding to the Golgi
membranes was found for both EGF and insulin
after AAF feeding of 2-85 days. The % specific
binding per 0.1 mg protein for EGF was 15.2
(control), 9.4 (2d AAF), 0.8 (21d AAF). For
insulin: 10 (control), 6 (2d AAF), 1.5 (21d AAF). A
similar decrease was noted for microsomes, but was
slower and less pronounced. Competition studies
with both Golgi and microsomal membranes
showed an AAF-induced decrease in the number
but not affinity of both EGF and insulin receptors.
To determine whether this decrease was a direct
toxic effect, rats were fed AAF for 3 mo. and
returned to a basal diet for a further 2mo. The
livers of such rats off all carcinogen also
demonstrated a lower binding to EGF and insulin.
Direct incubation of normal membranes in vitro
with AAF or its active metabolites hydroxy-AAF
or acetoxy-AAF produced no significant decrease in
the binding for EGF and insulin. Thus, carcinogen
feeding induced a rapid, apparently stable decrease
in the number of insulin and EGF receptors by a
mechanism other than toxic damage. This could be
due to altered receptor structure, synthesis, or
breakdown; or production of a factor which binds
to the insulin and EGF receptors.
Tumorigenicity and cytotoxicity of 5-azacytidine and
analogues
B.I. Carr' A. Riggs, J.G. Reilly & S. Dickman'
'Department ofMedical Oncology and Division of
Biology, City ofHope Natl. Medical Center, Duarte,
California, 91010, USA.
5-azacytidine (Aza-C) is known to inhibit
methylation in newly synthesized DNA and to
induce gene activation. It has been used in the
experimental treatment of acute leukaemia,
thalassaemia and sickle cell anaemia. This report
shows that it is also a carcinogen. Young adult
male F344 rats were given Aza-C 2.5-l0mgkg - i.p.
in saline twice weekly for 9 months and examined 9
months later. About 30% of the rats died before
the end of the experiment and could not 6e
evaluated. Of the survivors, the number of rats with270 PROCEEDINGS OF BACR 25TH AGM
tumours/number of rats examined were 17/20.
Controls 0/12. The tumour types were Leydig,
Sertoli and interstitial cell testis (10); invasive
squamous cell skin (3); adeno-carcinoma of lung (1)
and reticuloendotheliosis (1). A follow-up
experiment using Zza-C analogues has been initiated.
The cytotoxicity of Aza-C and analogues (all at
10-4M) was examined using a 24h viability assay
with normal rat hepatocytes. Results (%
survival/controls) were (av. of 6expts. =cytosine 85;
cytidine 77; 5-fluorocytosine 69; 5-fluorocytidine 47;
5-fluoro-2-deoxycytidine 62; 5-azacytidine 32; 5-aza-
2-deoxycytidine 63; 5,6-dihydro-5-azacytidine 50; 6-
azacytidine 67; pseudoisocytidine 70. Tetra-
hydrouridine, a deamination inhibitor, was not
toxic and did not increase the toxicity of any of the
above analogs at 10-6-10-2M. Thus, Aza-C is a
carcinogen in the rat. Aza-C, 5-fluorocytidine and
5,6-dihydro-Aza-C are toxic in vitro. The
deoxyribose analogues are less toxic than the ribose
analogues, suggesting that cytotoxicity may not be
mediated solely through DNA. In current in vivo
expts. a similar toxicity is observed as weight loss
with Aza-C and fluorocytidine but not with equi-
molecular amounts of their deoxy analogues.
Radiation-induced activation of 4-NQO and its
chemical consequences for DNA
C.L. Greenstock
Paterson Laboratories, Christie Hospital & Holt
Radium Institute, Manchester M20 9BX, UK.
Many chemicals undergo metabolic activation to
ultimate carcinogens. The subsequent interactions
of these reactive intermediates with critical cellular
targets are important precursors to malignant cell
transformation, and studies of the kinetic and
molecular processes may help in understanding the
overall mechanisms ofcarcinogenesis.
Irradiation of calf thymus DNA in the presence
of 4-NQO leads to the formation of trichloroacetic
acid precipitable, presumably covalent DNA-4-
NQO, complexes. When 4-NQO is present in
excess, the nucleophilic radiolysis species eaq and
02-- are principally responsible for adduct
formation, suggesting the radical anion 4-NQO-
and other reductive metabolites are toxic. The 4-
NQO also contributes to the enhancement of
radiolytic destruction of pyrimidine and purine
nucleotides in DNA, as monitored by HPLC
following enzyme hydrolysis. Pulse radiolysis
studies show that 4-NQO reacts with nucleic acid,
fatty acid and amino acid moieties, by free radical
redox reactions which may be involved in the
carcinogenic and cytotoxic effects of 4-NQO.
Metabolic activation of chrysene: Comparative
studies with rodent and human skin
A. Weston, R.M. Hodgson, A. Hewer & P.L.
Grover
Institute ofCancer Research: Royal Cancer Hospital,
Fulham Road, London SW3 6JB, UK.
In an attempt to assess the sensitivity of human
skin to polycyclic hydrocarbon carcinogenesis, the
metabolism and activation of hydrocarbons in
susceptible and resistant rodent skin in vivo and in
vitro is being examined and compared with that
occurring in human skin in short-term organ
culture. Chrysene, an environmental contaminant, is
weakly carcinogenic to mouse skin and is converted
by human and mouse skin in organ culture and by
mouse skin in vivo to chrysene-1,2-, 3,4- and 5,6-
dihydrodiols: A chrysene-triol that is believed to be
9-hydroxychrysene 1,2-diol was also found in some
experiments. Chrysene-1,2-diol is a precursor of
both the "bay-region" diol-epoxide, chrysene-1,2-
diol 3,4-oxide, and a triol-epoxide in mouse skin;
chrysene-1,2-diol is also more active than the parent
hydrocarbon as a tumour initiator in this mouse
tissue. The stereochemistry of the 1,2-diol and of the
other diols that are formed as metabolites of
chrysene by mouse skin was investigated by normal
phase hplc using columns that contained an
optically-active stationary phase and it was found
that (-)-enantiomers were formed almost
exclusively. When chrysene-treated mouse skin was
maintained in short-term organ culture,
dihydrodiols were released into the medium,
however, the enantiomeric purity of the 1,2-diol did
not vary as it accumulated over a 40h incubation
period. Levels of the chrysene-triol appeared to
reach equilibrium after 20-24h. The formation and
the enantiomeric purity of the chrysene-triol that is
formed by metabolism from optically-pure samples
of the chrysene-1,2-diol is being examined together
with the hydrocarbon-deoxyribonucleoside adducts
that are formed in human skin that has been
treated in short-term organ culture with chrysene.PROCEEDINGS OF BACR 25TH AGM 271
Frequency of exposure is more important than total
dose in determining carcinogenic response
R.M Hicks, J.A. Turton, K. Nandra, J. Gwynne, M.
Pedrick & E. Chrysostomou
School ofPathology, Middlesex Hospital Medical
School, London WIP 7LD, UK.
It is well known that in many tissues cancer
incidence is directly proportional to the dose of
carcinogen. This dose-response relationship is
substantially modified by the frequency of dosing.
F344 rats were given 150, 300 or 600mg of the
bladder carcinogen N-butyl-N-(4-hydroxybutyl)
nitrosamine (BBN) in 3, 6, 9 or 12 weekly
aliquots. The incidence of bladder tumours and
hyperplasias was assessed at 1, 13, 26 and 52 weeks
post-dosing. With equal numbers of aliquots there
was a clear dose-related response, but for each total
dose more and smaller aliquots produced a greater
response than fewer larger aliquots. The frequency
with which the tissue was exposed to BBN was
more important than the total dose; for example,
tumour incidence after 600mg split into 3 doses was
lower than after 300mg split into 6 or 150mg split
onto 12 aliquots.
These results emphasise the potential danger of
multiple low dose exposure to carcinogens when
attempting to assess risk factors. The results also
indicated that the urothelial hyperplasias were
precursors of the tumours.
Binding of benzo(a)pyrene to regions of DNA with
different concentrations of active and inactive genes
N.M. Mironov, K. Pal & P.L. Grover
Chester Beatty Laboratories, Institute ofCancer
Research: Royal Cancer Hospital, Fulham Road,
London SW3 6JB, UK.
The binding of benzo(a)pyrene (BP) to different
regions of DNA was investigated in nuclei prepared
from rat liver or hamster embryo cells. After
digestion of DNA in the nuclei by either
endogenous nuclease activity or restriction endo-
nuclease HaeIII, chromatin was fractionated by
suspending the nuclei in low ionic strength TM
buffer (1OmM Tris-HC1, pH 7.6 containing
0.2mM MgCl2): this treatment resulted in the
solubilization of about 60% of the chromatin. After
centrifugation, the insoluble material was
resuspended in TM buffer containing 2MNaCl,
which solubilized most of the remaining DNA and
left 0.5-5% of the nuclear DNA as insoluble, matrix-
bound material. Concentrations of active albumin
and inactive globin genes in fractions from rat-liver
nuclei were determined by dot-blot hybridization.
The ratio of albumin to globin genes in the matrix-
bound fraction was 50-100 fold higher than in the
low ionic strength soluble fraction. When rat-liver
nuclei were incubated with 3H-benzo(a)pyrene (BP)
before fractionation, the concentration of BP bound
to DNA was 3-fold higher in the fraction enriched
in active genes. Using hamster embryo cells, we
found that the concentration of adducts was 16-fold
higher in matrix-bound DNA than in DNA soluble
in low ionic strength buffer and appeared to persist
longer. The results suggest that active DNA
sequences may be some 100-1000 fold more
extensively modified by BP metabolites than
inactive sequences.
A preliminary report on the presence of reverse
transcriptase in canine milk
T.D. Littlewood, F.M. Tomley & L.N. Owen
University ofCambridge, Department ofGenetics,
Downing Street, Cambridge and Department of
Clinical Veterinary Medicine, Madingley Road,
Cambridge, UK.
The epidemiology of several mammalian
retroviruses has been studied and there is evidence
of milk-borne transmission. The possibility of such
a route of infection for a canine virus was
investigated in a population of eighty clinically
normal Beagle bitches. Significant poly
(rC):oligo(dG)-templated reverse transcriptase
activity was detected in milk from seven animals
following preparation with the gradient material
Metrizamide (Sigma), which is known to reduce the
influence of inhibitors present in the milk (Sanner,
1976, Cancer Res., 36, 405). This activity was
abolished in the presence of untreated milk and was
not due to deoxy nucleotidyl transferase. No
activity was detected in the cellular fraction of these
samples following short-term culture with IUdR,
and no virus-like particles were seen on electron
microscopic examination.
The activity present in milk from clinically
normal dogs requires further characterization and is
relevant to any survey of milk-borne transmission
of virus in diseased animals.272 PROCEEDINGS OF BACR 25TH AGM
Promotion of cell phenotypes by interleukin 3:
Evidence for different interaction mechanisms for
basophil and lymphoid lineages
J.M. Garland' & R. Palacios2
'Department ofImmunology, Medical School,
Manchester, UK., 2Basel Institutefor Immunology,
Basel, Switzerland
Interleukin 3 is recognised for its ability to (i)
induce 20a steroid dehydrogenase a T-cell
associated enzyme in nu/nu spleen cells and (ii)
promote cell lines in vitro. Studies have been done
to determine the phenotypes of cells promoted by
IL-3. They include most basophils, G/M-CFU and
CFU-S. Recently, a cloned pre-B IL-3 dependent
line has been isolated (Palacios, R. et al., submitted
1983) and we have investigated whether the
mechanism of dependency is the same as that for a
cloned basophil line. We have found: (i) both lines
respond to IL-3 withdrawal by rapidly reducing
lactic acid production; (ii) the basophil line does not
measurably absorb IL-3, but absorption is
associated with the lymphoid line; (iii) the basophil
line responds to exogenous ATP by maintaining
proliferation whereas the lymphoid line does not
and (iv) for the basophil line, exogenous ATP
suppresses lactic acid production. We conclude
firstly that in both lines IL-3 ultimately affects cell
respiration, but only in the basophil line is
exogenous ATP able to feedback regulate lactic
acid, supporting a role for IL-3 in cell respiration;
secondly, there are different mechanisms whereby
IL-3 interacts with basophils and lymphoid
precursors and thirdly that IL-3 may regulate
normal poesis through different interaction
mechanisms expressed by different lineages.
Cell promotion by interleukin 3: Inferences for its
involvement in a leukaemic process
J.M. Garland' B. Pleuvry2 & N.J.F. Dodd3
1Department ofImmunology, 2Department of
Pharmacology, Medical School, Manchester and
3Paterson Laboratories, Manchester, UK.
Interleukin 3, a murine 28Kd glycoprotein derived
from stimulated T-cells and a myelomonocytic
leukaemic cell line WEHI-3b, promotes survival
and proliferation of a number of in vitro cell lines.
We have investigated the mechanism of action of
IL-3 by measuring changes in cell metabolism in a
cloned dependent line when it is withdrawn. We
have found: (i) changes in cell membrane integrity
as measured by ESR and trypan blue exclusion are
late events; (ii) cells arrest preferentially in G2/M;
(iii) as determined by P02 and lactic acid
production, cell respiration in both WEHI and IL-3
dependent cells is mainly by anerobic glycolysis,
which is the first parameter to be affected by IL-3
withdrawal; (iv) IL-3 does not appear to affect
Ca"+ metabolism. These observations suggest that
IL-3 promotes directly or indirectly cell respiration;
for example by affecting perhaps glucose transport.
IL-3 is found in avascular nodules of WEHI-3b
cells growing in leukaemic mice. Garland et al.,
1983, Br. J. Cancer 48, 247. We hypothesise that
WEHI cells are leukaemic because they
constitutively produce a factor which promotes
anerobic respiration.
Studies of the mechanism of enhancement of natural
killer cell activity by a streptococcal preparation
S.E. Christmas & M. Moore
Immunology Department, Paterson Laboratories,
Christie Hospital & Holt Radium Institute,
Manchester M20 9BX, UK.
The streptococcal immunopotentiator OK432 has
been found to enhance the natural killer (NK)
activity of human peripheral blood mononuclear
cells (PBMC) in vitro (Wahangi et al., 1982, JNCI,
69, 807). Clinical trials in patients with
carcinomatous pleural effusions gave promising
results possibly due to the enhancement of NK
activity in vivo (Uchida & Micksche, 1982, Int. J.
Cancer 31, 1). The aims of the present experiments
were to investigate the cellular requirements for the
activation of NK cells by OK432 and the mechanism
of its action. Depletion of monocytes to as low as
0.3% of PBMC using plastic and nylon wool
adherence failed to prevent the enhancement of NK
activity by OK432. Supernatants from OK432-
treated unseparated and non-adherent PBMC were
able to enhance the NK activity of fresh cells
following overnight preincubation. Supernatants
were assayed for interleukin-2 (IL-2) and interferon
(IFN) activities and it was found that IL-2
production was not tightly linked to NK enhancing
ability as in most experiments non-adherent cells
produced little or no IL-2 while still producing
significant amounts of NK enhancing activity. The
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linked to NK enhancing capacity but there were
indications that an additional factor(s) was involved
as supernatants with equal IL-2, IFN-oa and IFN-y
activities had differing NK enhancing abilities. An
anti-IFN-a antiserum slightly decreased NK
enhancing activity and overnight treatment at pH2
followed by re-neutralisation almost completely
abolished activity. If a factor(s) other than IFN-oa
and -y and IL-2 is involved in the enhancement of
NK activity by OK432 it appears to be labile at
pH2.
Metastases and surface glycoproteins in relationship
to tumour implantation site
G.A. Turner, W.-S. Chan & A. Jackson
University Department ofClinical Biochemistry and
Metabolic Medicine, Royal Victoria Infirmary,
Newcastle upon Tyne, UK.
A previous study (Chan et al., 1984, Br. J. Cancer,
in press) of a lymphosarcoma and its liver
metastases suggested that the site of tumour growth
is important in affecting the surface expression of
certain Wheat Germ Agglutinin (WGA) binding
proteins. This finding has been further investigated
by directly implanting tumour into different sites,
examining the subsequent patterns of tumour
spread, and analysing the composition of the
proteins extracted from the local tumour by using
electrophoresis and 1211-WGA labelling. The sites
tested were kidney, liver, muscle, peritoneal cavity
(p.c.), spleen, subcutaneous and lung/thorax. The
tumour grew in all sites, but its metastatic ability
and distribution varied. Extensive liver metastases
along with lymph node enlargement were a
common finding for all sites, except for p.c. and
thorax where liver involvement occurred
infrequently. Extra-hepatic metastases also varied,
being virtually non-existent for liver and spleen,
fairly frequent for kidney and muscle and
occasionally found for the subcutaneous site. Site
also affected the extent of WGA binding. Strong
binding patterns were seen for tumour extracts
from kidney, muscle and the subcutaneous site, i.e
the sites that formed the most extra-hepatic
metastases. These results emphasize the importance
of site in influencing metastatic properties and
suggest that site-modulated tumour surface
composition may have a role to play in this
process.
In vitro studies of fibroblasts derived from patients
with carcinoma of the breast
P. Durning, S. Schor & R.A. Sellwood
Department ofMedical Oncology, Christie Hospital
& Holt Radium Institute, Wilmslow Road,
Manchester, UK.
The epithelial cells in a tumour are regarded by
most authorities to be responsible for the malignant
properties of a tumour. There is considerable
evidence that stromal cells, in particular fibroblasts,
influence the behaviour of epithelial cells.
Fibroblasts derived from some tumours have been
shown recently to exhibit some of the properties
used to define the transformed phenotype in vitro.
Fibroblasts derived from 24 carcinomas of the
breast were examined in several assays commonly
used to define transformation in vitro. No
abnormalities of morphology, growth, serum
requirement or the ability to contract a gel of
hydrated collagen were found. We have demon-
strated that normal and transformed cells show a
consistent difference in their ability to migrate into
a collagen gel. Apparently normal fibroblasts from
eight patients with carcinomas of the breast showed
a normal pattern but 16 patients showed a trans-
formed pattern of migration. The relationship
between the transformed pattern of migration and
clinical indices of prognosis such as the presence of
lymph node metastasis was statistically significant
at the 3% level.
Fibroblasts derived from apparently normal skin
of each of these patients were examined and also
showed the same patterns of migration.
The implications of this finding in relation to the
systemic nature of malignancy will be discussed.
Patterns of cross sensitivity in the responses of clonal
subpopulations isolated from RIF-1 mouse sarcoma
to selected nitrosoureas and nitrogen mustards
J.G. Reeve, K.A. Wright & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge CB2 2QH,
UK.
Clonal subpopulations isolated from the RIF-1
mouse sarcoma differ markedly in their response to
in vitro treatment with melphalan and CCNU. For
melphalan treatment drug sensitivity is independent
of the ploidy level of individual clones. For CCNU
treatment a clear relationship exists between drug
sensitivity and ploidy with tetraploid and octoploid274 PROCEEDINGS OF BACR 25TH AGM
clones being markedly more resistant to drug
treatment than diploid clones. In the present study
RIF-1 clones growing in log phase culture were
treated for 1 h at 37°C with appropriate
concentrations of nitrogen mustard, aniline mustard
and chlorambucil, and with nitrosoureas BCNU,
MeCCNU and chlorozotocin, in order to evaluate
whether or not the different physiochemical and
biological activities of these agents would affect the
patterns of drug sensitivity described above.
Irrespective of the different lipophilicities and
transport mechanisms of the nitrogen mustards
used in the present study, RIF-1 clones showed the
same pattern of sensitivity when exposed to either
melphalan, nitrogen mustard, aniline mustard or
chlorambucil. Similarly RIF-1 clones when exposed
to BCNU, MeCCNU and chlorozotocin showed
the same pattern of sensitivity as that observed for
CCNU treatment. These data suggest (a) that the
variation in the sensitivity of RIF-1 clones to
treatment by the nitrogen mustards is unlikely to
reflect differences in either membrane permeability
or in drug transport mechanisms within the cells (b)
that the ploidy dependent nitrosourea responses
shown by RIF-1 clones similarly do not reflect
differences in membrane permeabilities or in cell
sensitivities to relative alkylation versus carba-
moylation. Furthermore, it is likely that a common
mechanism may predominantly govern response to
the different nitrosoureas, whereas a different
common mechanism may govern response to the
nitrogen mustards.
Nitrogen mustard selectively inhibits rubidium influx
into murine L1210 leukaemia cells
C. Wilcock, J.A. Hickman & S.B. Chahwala
CRC Experimental Chemotherapy Group,
Department ofPharmacy, University ofAston,
Birmingham B5 7ET, UK.
The interaction of antineoplastic drugs with the
plasma membrane may contribute or be causative
to their cytotoxicity. It has been shown that
nitrogen mustard (HN2) inhibited the net
accumulation of 86Rb+ (a potassium congener) into
mouse plasmacytoma cells (Baxter et al., 1982,
Biochem. Pharmacol., 31, 1773). This inhibition was
suggested to result from the inactivation of the
enzyme Na+K+ATPase, which plays an important
role in the control of cell proliferation. In order to
define more fully these observations on net 86Rb+
accumulation, the effects of HN2 (10-5M=_ID99)
on the component influx and efflux of 86Rb+ were
examined in L1210 cells incubated in Krebs-Ringer
bicarbonate buffer (pH7.4) for various times. The
table shows the percentage decrease in equilibrium
loading and initial rates of uptake and efflux of
86Rb+ in treated cells compared to controls.
86Rb+ 86Rb+ 86Rb+
Time (h) A Viability loading uptake efflux
1 4 7 37 3
2 6 19 63 3
3 14 52 83 17
4 51 74 89 73
After 3h of incubation, cell viability, as estimated
by trypan blue exclusion, was >86% of control.
The equilibrium loading of the cells with 86Rb+
was reduced at this time by 52% as a result of an
83% inhibition of 86Rb+ influx. The negligible
effect on 86Rb+ efflux at 3h increases to 73%
inhibition at 4h concomitant with a loss in cell
viability. These results suggest that the inhibition of
86Rb+ equilibrium loading is not due to generalised
membrane damage, but rather to a specific lesion.
Structural requirements for the cytotoxicity of CB
1954 (2,4 dinitro-5-aziridinyl benzamide) towards
Walker cells
K.J. Hunter', J.M. Walling1, I.J. Stratford1 & D.
Wilman2
1MRC Radiobiology Unit, Harwell, Didcot, Oxon
and 2Institute of Cancer Research, Sutton, Surrey,
UK.
The Walker 256 mammary carcinoma has been
found to be uniquely sensitive to the
monofunctional alkylating agent CB 1954 (Cobb et
al., 1969, Biochem. Pharmacol., 18, 1519). We have
investigated the in vitro sensitivity of a pair of cell
lines derived from this tumour towards CB 1954
and a range of structural analogues. The parent cell
line (WS) is sensitive to bifunctional alkylating
agents, whereas the derived cell line (WR) is
resistant. Both cell lines show the identical exquisite
toxicity to CB 1954 but towards other mono-
functional agents the two cell lines show similar
sensitivities to other normal, cultured mammalian
cell lines.
Progressive methyl substitution of the amide
results in a concomitant loss of cytotoxicity
towards the Walker cells, e.g. 5MiM CB 1954 for
one hour reduced survival to 10-2 whereas 50yM
of the methyl amide was required to give the same
degree of cell kill. (N.B. >2mM is required for
both compounds in V79 cells). Replacement of onePROCEEDINGS OF BACR 25TH AGM 275
of the nitro groups with an amine resulted in a
complete loss of toxicity as did opening of the
aziridine to give a dimethyl-amine. We have
evidence to suggest that at least part of the
cytotoxicity of CB 1954 is due to mitotic inhibition
and NAD depletion.
Potentiation of the effects of bleomycin and BCNU
on A549 cell cultures by inhibitors of poly(ADP-
ribose) polymerase
D.A. Gray, J.M. Lunn & A.L. Harris
Cancer Research Unit, University ofNewcastle upon
Tyne, UK.
Fluoroacetate production by fluoroethylnitrosoureas
R.A. Brennan & M.J. Tisdale
CRC Experimental Chemotherapy Group,
Department ofPharmacy, University ofAston,
Birmingham B4 7ET, UK.
The role of fluoroacetate in the toxicity and
antitumour activity of the fluoroethylnitrosoureas,
BFNU [N,N1-bis (2-fluoroethyl)-N-nitrosourea] and
FCNU [N-(2-fluoroethyl)-N-cyclohexyl-N-nitro-
sourea] has been studied in CBA mice bearing the
TLX5 lymphoma either sensitive (TLXS) or
resistant (TLX RT) to nitrosoureas. Any fluoro-
acetate formed might be expected to be converted
into fluorocitrate, which has a blocking effect on
aconitase. This leads to an accumulation of citrate
in the affected tissue and cell death.
Treatment of mice bearing the TLXS tumour
with either BFNU or FCNU caused an elevation in
the citrate levels of heart, kidney and tumour, but
not the liver 24h after drug administration. Heart
citrate levels were maximally elevated 10-fold, while
the levels in kidney and tumour were increased 3 to
6-fold. A similar differential response of liver and
kidney to fluoroacetate poisoning has previously
been reported (Spencer & Lowenstein, 1967,
Biochem. J., 103, 342), and may be a function of
the different specificities of acetyl-CoA synthetase
of liver and kidney. Deproteinised supernatants
from heart, kidney and tumour inhibited purified
aconitase.
Treatment of mice bearing the resistant tumour
(TLX RT) with either BFNU or FCNU also
caused an elevation of citrate levels in heart, kidney
and tumour. Since these agents have no antitumour
activity against this tumour it suggests that
fluoroacetate formation is not related to therapeutic
efficacy, but may be associated with generalised
toxicity of the fluoroethylnitrosoureas.
Poly(ADP-ribose) polymerase has been implicated
in the process of DNA repair, specifically at the
ligation step (Creissen & Shall, 1982, Nature, 296,
271).
Exposure of A549 cells (derived from a human
lung carcinoma) to Bleomycin (BLM,5-
500 ugml-1) for 30min caused extensive DNA
strand breaking, as revealed by alkaline sucrose
gradient centrifugation. Rejoining of the strands
was inhibited by 3-acetamidobenzamide (3-AAB,
2.5mM). BLM (50-500pgml-1) also stimulated
poly(ADP-ribose) polymerase activity in the cells,
as measured by incorporation of 3H-NAD into
TCA-insoluble material, and this stimulation was
suppressed by 3-aminobenzamide (3-AB, 3mM) or
3-AAB (2.5mM). Cell survival at 5 days, following
a 30min exposure to BLM (50pgml-1), was
decreased 90%. The presence of 3-AAB (2.5mM)
in the growth medium potentiated this effect
approximately two-fold.
BCNU (50 pM, 30min) produced the same level
of cytotoxicity as BLM (50pgml-1, 30min), but
the effect of BCNU was potentiated much more
markedly (5-10-fold) by 3-AAB (2.5mM).
However, it failed to produce either DNA strand
breaks, detectable by alkaline sucrose gradient
centrifugation, or a stimulation of poly(ADP-
ribose) polymerase activity.
These results suggest that poly(ADP-ribose)
polymerase inhibitors have other biochemical
effects.
Clonogenicity of human lung cancer cells
P. Twentyman & G. Walls
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
We are interested in studying the biological and
therapeutic heterogeneity of cells from human lung
cancers and to do this we wish to isolate clonal
subpopulations of cells either directly from clinical
material or from very early in vitro cultures. We
have, therefore, carried out experiments to
determine the optimal in vitro cloning conditions276 PROCEEDINGS OF BACR 25TH AGM
for human lung cancer cells. A number of
established human cancer cell lines have been used,
growing either in vitro or as xenografts in nude
mice. In addition we have used several early
cultures established from marrow or lymph node
biopsy specimens taken from small cell lung cancer
patients and grown in defined HITES medium
(Simms et al., 1980, Cancer Res., 40, 4356) with or
without 2.5% foetal calf serum, as well as
specimens directly from the clinic. In a comparison
of two soft agar cloning assays for a wide range of
specimens we found a higher plating efficiency in
the method of Courtenay & Mills, (Br. J. Cancer.,
1978, 37, 261) than in the double-layer technique
described by Carney et al., 1980, (Cancer Res., 40,
1820). In addition the colonies were larger and
easier to isolate using the former technique,
probably due to the repeated medium replenishment
involved. Varying the conditions of the Courtenay
assay produces different effects for different cell
types. For a small cell lung cancer line, the presence
of rat red cells in the agar plug was a critical factor
whereas it was less important for an
adenocarcinoma cell line and a large cell anaplastic
cell line. In general, growth in atmospheres
containing 5% or less of oxygen was better than in
20% oxygen. Addition of irradiated feeder cells was
of variable value. These factors are closely inter-
related and do not operate as independent
variables.
Two human ovarian adenocarcinoma cell lines
derived before and after clinical resistance to
cytotoxic drugs
C.R. Wolf', S.S. Lawrie', D.J. Adams', A.R.R.
Laudoniol, I.P. Hayward', M.A. McIntyre2, K.E.
Buckton3 & J.F. Smyth1
'Imperial Cancer Research Fund, Medical Oncology
Unit, 2Dept. ofPathology and 3MRC Clinical and
Population Cytogenetics Unit, Western General
Hospital, Edinburgh, UK.
Two human ovarian cell lines, PEOI and PEO4,
have been established from ascitic fluid samples of
a patient before and after the development of
clinical resistance to a combination of 5-
fluorouracil, chlorambucil and cis-platinum. The
two cell lines exhibited certain similarities but also
some significant differences. Both lines contained
vesicular nuclei with prominent and occasional
multiple nucleoli and vacuolated cytoplasm. "Signet
ring" mucin containing cells were also present. A
significant number of rearranged chromosomes
were observed in cell lines PEOI and PEO4.
Abnormal chromosomes in common were 3, 9, 13
and 22. PEO4 had a chromosome 8 and 17 not
identifiable in PEOl. Significant differences
between PEOl and PEO4 - in their doubling times
(33h vs 24h), plating efficiency in plastic (0.8% vs
5.7%) and in agar (0.1% vs 4.0% early passage,
4.6% vs 14.0% later passage), contact inhibition
and sensitivity to trypsin treatment were observed.
In addition glutathione and glutathione S-
transferase activities (components intimately
involved with the deactivation of alkylating agents)
were approximately 2-5 fold higher in PEO4 than
PEOI. Mean glutathione concentrations were 0.8
and 5.9nmol 106 cells-' and transferase activities
were 35 vs 159nmol conjugate formed
min-1106cells- . Preliminary experiments indicate
a much higher susceptibility of PEO1 to cis-
platinum than PEO4. For drugs which require
metabolic activation the clonogenic Courtenay
assay has been modified to incorporate an
activating system. In this system cyclophosphamide
was highly active against PEO4.
Phenotypic analysis of cell lines grown from
Hodgkins Disease (HD) biopsy material
D.B. Jones', S. Scott2, H. Stein3 & D.H. Wright1
'Departments ofPathology, Southampton and
3Berlin and 2Department ofHaematology, Corkridge
Hospital, Leeds, UK.
The origin of the Reed-Stemnberg cell (RS) and
Mononuclear Hodgkins cell (Mhc) characteristic of
HD remains a mystery. Previous studies have
suggested an origin from T cells, B cells or
macrophages. Cell lines grown in Southampton and
Germany from HD Biopsy tissue have enabled us
to revise opinions on the RS/MHc lineage. Two
tetraploid cell lines (CO and L428 have been
examined in detail. The cells do not synthesize
immunoglobulin and are negative both for the
Epstein Barr Nuclear antigen (EBNA) and EB
transformed lymphoblastoid line antigens. When
examined with a panel of moncolonal antibodies
the cells do not express a phenotype characteristic
of T cells, B cells or macrophages though staining
(sometimes intracellular) is observed with some
myeloid/macrophage antibodies and with a
minority of anti-T cell antibodies. Histiocyte
markers (Isaacson & Jones, 1983, Histochem. J., 15,
621) are absent. The unique phenotype is confirmed
by the observation that a monoclonal antibody ki-
1, raised to L428 cells which stains both cell lines
and RS and MHC cells also identifies a unique
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and tonsils. Isoelectric focussing shows that CO
exhibits a unique esterase isoenzyme pattern with
major bands of PI less than 5.4. The data suggest
that RS and MHC are derived from a unique cell
population. The ability of both lines to bind T cells
may be relevant to the stromal reaction observed in
HD.
Human tumour cell lines established from xenografts
in immunodeficient mice or rats. Characterisation by
horse-radish peroxidase visualisation of Con-A
binding sites on Western blots of 2-D PAGE
J. Walton, D. Winterbourne, A. Fiennes,
J. Hermon-Taylor & A. Grant
Department ofSurgery, St. George's Hospital
Medical School, London SW17 ORE, UK.
Four primary tumour explants obtained from
patients with pancreatic (WAD), colonic (CAS,
CAU; Davies et al., 1981, Br. J. Can. 43, 53), and
renal cancer (GYL; Matthews et al., 1981, Urol.
Res., 10, 293) which initially grew only as
xenografts in nude mice (nu/nu) or rats (rnu/rnu)
have been established in tissue culture. Xenografts
had to be passaged at least 4 times in vivo before in
vitro growth was maintained. All of the cell lines
had a human karyotype with no evidence of
infiltrating mouse stroma. Each retained its
tumourgenicity, could be regrown as a xenograft
and showed a characteristic morphology in culture.
Glycoproteins on 2-dimensional polyacrylamide
gel electrophoresis of Urea/NP-40 extracts from
tumour cells were detected on Western blots with
Con-A visualised with horseradish peroxidase. The
majority of the Con-A binding glycoproteins were
common to all cell lines but the intensity of
labelling vaincd atnd each cell line exhibited
characteristic marker glycoproteins.
Astrocytoma xenografts in the choice of a second
generation triazene
D.E.V. Wilman', N.J. Bradley2 & S.G. Richardson2
'CRC Laboratory, Institute ofCancer Research,
Sutton, Surrey, SM2 5PX, and 2Chester Beatty
Laboratories, Institute ofCancer Research, Fulham
Road, London, SW3 6JB, UK.
We have reported several times in the past on our
investigations related to the search for an aryl-
triazene as a suitable second-generation analogue of
5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide
(DTIC, Dacarbazine). Our original approach,
which included a detailed structure-activity study
(Connors et al., 1976, Biochem. Pharmacol., 25,
241), was aimed at overcoming problems which
reputedly arose from the photodecomposition of
DTIC. As this is no longer regarded as a problem,
though not losing sight of this objective, we have
now become interested in the response of
astrocytomas to these compounds. Grade IV
astrocytoma xenografts grown as s.c. flank implants
in immune deprived mice are sensitive to a number
of clinical drugs, e.g. nitrosoureas, procarbazine,
DTIC and a number of aryltriazenes, whereas the
Grade III tumours show relatively little response.
We have chosen one of these sensitive Grade IV
astrocytomas (508) for a more detailed study. When
implanted intracerebrally this tumour is sensitive
only to nitrosoureas and aryltriazenes, compounds
which meet Levin's criteria for compounds to cross
the blood-brain barrier (J. Med. Chem., 1980, 23,
682). The flank implant of this tumour is sensitive
to a range of aryldialkyltriazenes resulting in the
"cure" of a number of implants. Testing of these
compounds in the intracranial system will assist the
choice of a suitable second-generation triazene to
recommend for preclinical toxicology.
The malignant transformation of mouse fibroblasts in
the presence of human tumour xenografts
S. Sparrow', M. Jones2, S. Billington1 & B. Stace'
'MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey, & 2lnstitute of Cancer
Research, Clifton Avenue, Sutton, Surrey, UK.
A human tumour xenograft programme designed to
study chemotherapeutic agents has involved the
transplantation of 75 different tumours into
athymic mice over a period of 4 years. Some of
these tumours have been passaged more than 20
times. During this period two tumours, an oat cell
carcinoma of the lung and an ovarian carcinoma
showed striking changes in their biology. There was
a shortening of the passage interval from 259 days
to 17 days and 274 days to 20 days respectively
(tumours were passaged when they had reached a
mass of 1-2g), the karyotype changed from human
to mouse, the LDH isoenzymes of the tumour
developed mouse characteristics and the tumours
became invasive with ulceration of the skin and
metastases to regional lymph nodes and the lung,
which is a feature rarely seen in xenografts.
Histological examination of the tumours over three
passages showed a gradual replacement of the278 PROCEEDINGS OF BACR 25TH AGM
human xenografts by proliferative fibroblastic
tissue. Transformation of mouse fibroblasts when
human tumour xenografts are propagated in vitro
was demonstrated some time ago (Tveit et al., 1980,
Br. J. Cancer, 41, 725) and it was recently shown
that a similar phenomena could occur in vivo
(Beattie et al., 1982, PNAS, 79, 3033).
Preliminary results with new human tumour
xenograft lines grown in immune-deprived mice
J.A. Hanson, A. Pritchard & J.L. Moore
Department ofRadiobiology, Velindre Hospital,
Cardiff, UK.
CBA/Lac mice were immune-deprived by
thymectomy and irradiation (Steel et al., 1978, Br.
J. Cancer, 37, 224) and were kept for up to 6 weeks
post-irradiation for subcutaneous tumour im-
plantation. Thymectomised mice were housed in
animal isolators. Xenografting attempts from 25
patient tumour samples, using either cell aggregates
from fluid samples (7/25), tissue fragments from
solid samples (11/25), or occasionally, cells from
short-term culture (7/25) resulted in 7 tumour
"takes" of which 4 have been passaged a number of
times. Three of these new lines have been partially
characterised. V2 is an adenocarcinoma of the
colon. V7 and V24 are both from primitive cell
type ovarian tumours. Quinacrine dihyrochloride
fluorescence (Muller, 1976, Stain Technol., 51, 287),
karyology or isoenzyme studies have confirmed the
human origin of V2, V7 and V24. Sensitivity in
vitro of V7 to vinblastine and cisplatin has been
measured periodically over 16 months, using a soft
agar assay (Courtenay & Mills, 1978, Br. J. Cancer,
37, 261) and was found to be moderately stable,
though the original patient sample obtained after
chemotherapy and radiotherapy was markedly more
resistant to vinblastine.
The generation of monoclonal antibodies against
human pancreatic exocrine cancer
A. Grant, P. Harris, B. Pyml & J. Hermon-Taylor
Department of Surgery, St. George's Hospital
Medical School, London SW17 ORE, and 'ICRF,
Lincoln's Inn Fields, London, UK.
Five different immunization methods for the
stimulation of mouse spleen cells to produce
antibodies selective for human pancreatic cancer
cells (GER) have been investigated. Spleen cells
from mice immunized with (i) viable GER cells, (ii)
pancreatic tumour xenografts, (iii) serum from nude
mice bearing pancreatic tumour xenografts, (iv)
reconstituted chimeric animals and (v) spleens taken
directly from nude mice bearing tumour xenografts,
have been fused with mouse myeloma cells NSO/1.
Supernatants from hybrid containing wells were
tested for immunoglobulin (Ig) production by
screening against a pannel of glutaraldehyde fixed
human tumour cells and pooled normal human
lymphocytes using sheep anti-mouse Ig urease-
conjugated antibody in a modified ELISA assay.
Using all methods, 10-20% of the hybrid wells
produced Ig which bound to pancreatic tumour
cells but only 2-3% (160/849 wells) showed some
selectivity for these cells. Ten of these wells have
retained their selectivity on cloning. The antigens to
which these antibodies (mainly IgGl) bind are being
characterised by immunofluorescence and immuno-
peroxidase staining of fresh and frozen tissue
sections and 2-D PAGE. Mice immunized with
tumour-bearer serum or reconstituted chimeric
animals yielded fewer hybrid containing wells and
fewer colonies per well, but proportionally more of
these were selective for GER cells. Successful
fusions were obtained from the spleens of nude
mice bearing pancreatic tumour despite their
incomplete T-cell system.